0001878313 2026-01-01 2026-03-31 0001878313 2026-05-11 0001878313 2026-03-31 0001878313 2025-12-31 0001878313 2025-01-01 2025-03-31 0001878313 us-gaap:PreferredStockMember 2025-12-31 0001878313 us-gaap:CommonStockMember 2025-12-31 0001878313 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001878313 us-gaap:RetainedEarningsMember 2025-12-31 0001878313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001878313 us-gaap:PreferredStockMember 2024-12-31 0001878313 us-gaap:CommonStockMember 2024-12-31 0001878313 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001878313 us-gaap:RetainedEarningsMember 2024-12-31 0001878313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001878313 2024-12-31 0001878313 us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001878313 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001878313 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001878313 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001878313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001878313 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001878313 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001878313 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001878313 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001878313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001878313 us-gaap:PreferredStockMember 2026-03-31 0001878313 us-gaap:CommonStockMember 2026-03-31 0001878313 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001878313 us-gaap:RetainedEarningsMember 2026-03-31 0001878313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001878313 us-gaap:PreferredStockMember 2025-03-31 0001878313 us-gaap:CommonStockMember 2025-03-31 0001878313 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001878313 us-gaap:RetainedEarningsMember 2025-03-31 0001878313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001878313 2025-03-31 0001878313 MAIA:AtTheMarketOfferingAgreementMember 2025-01-01 2025-03-31 0001878313 us-gaap:PrivatePlacementMember 2025-01-01 2025-03-31 0001878313 MAIA:PrivatePlacementOfferingOneTwentyTwentyFiveMember 2026-01-01 2026-03-31 0001878313 MAIA:PrivatePlacementOfferingOneTwentyTwentyFiveMember 2025-01-01 2025-03-31 0001878313 MAIA:PrivatePlacementOfferingTwoTwentyTwentyFiveMember 2026-01-01 2026-03-31 0001878313 MAIA:PrivatePlacementOfferingTwoTwentyTwentyFiveMember 2025-01-01 2025-03-31 0001878313 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001878313 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001878313 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001878313 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001878313 srt:MinimumMember MAIA:FGMKLLCAndFGMKBusinessHoldingsLLCMember 2026-01-01 2026-03-31 0001878313 MAIA:FGMKLLCAndFGMKBusinessHoldingsLLCMember 2026-01-01 2026-03-31 0001878313 MAIA:FGMKLLCAndFGMKBusinessHoldingsLLCMember 2025-01-01 2025-03-31 0001878313 MAIA:FGMKBusinessHoldingsLLCMember us-gaap:PrivatePlacementMember 2025-02-01 2025-02-28 0001878313 MAIA:FGMKBusinessHoldingsLLCMember us-gaap:PrivatePlacementMember 2025-02-28 0001878313 MAIA:StanSmithMember us-gaap:PrivatePlacementMember 2025-02-01 2025-02-28 0001878313 MAIA:StanSmithMember us-gaap:PrivatePlacementMember 2025-02-28 0001878313 MAIA:RamiroGuerreroMember us-gaap:PrivatePlacementMember 2025-02-01 2025-02-28 0001878313 MAIA:RamiroGuerreroMember us-gaap:PrivatePlacementMember 2025-02-28 0001878313 MAIA:StanSmithMember us-gaap:PrivatePlacementMember 2025-03-01 2025-03-31 0001878313 MAIA:StanSmithMember us-gaap:PrivatePlacementMember 2025-03-31 0001878313 MAIA:RamiroGuerreroMember us-gaap:PrivatePlacementMember 2025-03-01 2025-03-31 0001878313 MAIA:RamiroGuerreroMember us-gaap:PrivatePlacementMember 2025-03-31 0001878313 us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001878313 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001878313 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001878313 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001878313 us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001878313 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001878313 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001878313 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001878313 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001878313 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-01-01 2026-03-31 0001878313 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-01-01 2025-03-31 0001878313 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001878313 2022-08-01 0001878313 2025-05-22 0001878313 MAIA:HCWainwrightAndCoLLCMember MAIA:AtTheMarketOfferingAgreementMember 2024-02-14 0001878313 MAIA:HCWainwrightAndCoLLCMember srt:MaximumMember us-gaap:CommonStockMember MAIA:AtTheMarketOfferingAgreementMember 2024-02-14 0001878313 MAIA:HCWainwrightAndCoLLCMember srt:MaximumMember us-gaap:CommonStockMember MAIA:AtTheMarketOfferingAgreementMember 2024-03-25 0001878313 MAIA:HCWainwrightAndCoLLCMember srt:MaximumMember us-gaap:CommonStockMember MAIA:AtTheMarketOfferingAgreementMember 2024-12-23 0001878313 MAIA:HCWainwrightAndCoLLCMember srt:MaximumMember us-gaap:CommonStockMember MAIA:AtTheMarketOfferingAgreementMember 2025-03-22 0001878313 MAIA:HCWainwrightAndCoLLCMember MAIA:AtTheMarketOfferingAgreementMember 2025-01-01 2025-03-31 0001878313 MAIA:HCWainwrightAndCoLLCMember MAIA:AtTheMarketOfferingAgreementMember 2025-03-31 0001878313 us-gaap:PrivatePlacementMember 2025-02-24 2025-02-24 0001878313 us-gaap:PrivatePlacementMember 2025-02-24 0001878313 us-gaap:PrivatePlacementMember 2025-03-03 2025-03-03 0001878313 us-gaap:PrivatePlacementMember 2025-03-03 0001878313 MAIA:ConfidentiallyMarketedPublicOfferingMember 2026-03-04 2026-03-04 0001878313 MAIA:ConfidentiallyMarketedPublicOfferingMember 2026-03-04 0001878313 MAIA:ConfidentiallyMarketedPublicOfferingMember 2026-01-01 2026-03-31 0001878313 MAIA:ConfidentiallyMarketedPublicOfferingMember 2026-03-31 0001878313 MAIA:ConfidentiallyMarketedPublicOfferingMember 2026-03-09 2026-03-09 0001878313 MAIA:ConfidentiallyMarketedPublicOfferingMember 2025-03-09 0001878313 MAIA:ConfidentiallyMarketedPublicOfferingMember 2026-03-09 0001878313 us-gaap:RestrictedStockMember 2026-01-01 2026-03-31 0001878313 us-gaap:RestrictedStockMember 2026-03-31 0001878313 us-gaap:RestrictedStockMember 2025-03-31 0001878313 us-gaap:IPOMember 2022-08-01 0001878313 us-gaap:IPOMember 2022-08-01 2022-08-01 0001878313 us-gaap:OverAllotmentOptionMember 2022-08-03 0001878313 MAIA:BlackSholesMethodMember 2022-08-03 0001878313 MAIA:BlackSholesMethodMember 2022-08-03 2022-08-03 0001878313 us-gaap:IPOMember MAIA:BlackSholesMethodMember 2026-03-31 0001878313 us-gaap:IPOMember MAIA:BlackSholesMethodMember 2025-12-31 0001878313 us-gaap:IPOMember MAIA:BlackSholesMethodMember 2026-01-01 2026-03-31 0001878313 us-gaap:IPOMember MAIA:BlackSholesMethodMember 2025-01-01 2025-03-31 0001878313 MAIA:RegisteredDirectOfferingMember 2023-11-17 0001878313 MAIA:RegisteredDirectOfferingMember 2023-11-17 2023-11-17 0001878313 MAIA:RegisteredDirectOfferingMember 2024-09-30 0001878313 MAIA:RegisteredDirectOfferingMember MAIA:BlackSholesMethodMember 2024-01-01 2024-09-30 0001878313 MAIA:RegisteredDirectOfferingMember MAIA:BlackSholesMethodMember 2023-11-17 0001878313 MAIA:RegisteredDirectOfferingMember MAIA:BlackSholesMethodMember 2023-11-17 2023-11-17 0001878313 MAIA:RegisteredDirectOfferingMember MAIA:BlackSholesMethodMember 2026-03-31 0001878313 MAIA:RegisteredDirectOfferingMember MAIA:BlackSholesMethodMember 2025-12-31 0001878313 MAIA:RegisteredDirectOfferingMember MAIA:BlackSholesMethodMember 2026-01-01 2026-03-31 0001878313 MAIA:RegisteredDirectOfferingMember MAIA:BlackSholesMethodMember 2025-01-01 2025-03-31 0001878313 MAIA:RegisteredDirectOfferingMember 2023-11-15 0001878313 MAIA:RegisteredDirectOfferingMember 2023-11-15 2023-11-15 0001878313 MAIA:RegisteredDirectOfferingMember 2026-03-31 0001878313 MAIA:RegisteredDirectOfferingMember 2025-12-31 0001878313 MAIA:RegisteredDirectOfferingMember 2026-01-01 2026-03-31 0001878313 MAIA:RegisteredDirectOfferingMember 2025-01-01 2025-03-31 0001878313 us-gaap:PrivatePlacementMember 2024-03-28 2024-03-28 0001878313 us-gaap:PrivatePlacementMember 2024-03-28 0001878313 us-gaap:PrivatePlacementMember 2024-05-31 0001878313 MAIA:AmendmentOfWarrantAgreementsMember us-gaap:PrivatePlacementMember 2024-05-31 0001878313 MAIA:AmendmentOfWarrantAgreementsMember us-gaap:PrivatePlacementMember 2026-03-31 0001878313 MAIA:AmendmentOfWarrantAgreementsMember us-gaap:PrivatePlacementMember 2025-12-31 0001878313 MAIA:AmendmentOfWarrantAgreementsMember us-gaap:PrivatePlacementMember 2026-01-01 2026-03-31 0001878313 MAIA:AmendmentOfWarrantAgreementsMember us-gaap:PrivatePlacementMember 2025-01-01 2025-03-31 0001878313 us-gaap:PrivatePlacementMember 2024-02-24 2025-02-24 0001878313 srt:DirectorMember MAIA:TwoThousandTwentyOneEquityIncentivePlanMember us-gaap:PrivatePlacementMember 2025-02-24 0001878313 srt:DirectorMember us-gaap:PrivatePlacementMember MAIA:BlackSholesMethodMember 2025-02-24 0001878313 srt:DirectorMember us-gaap:PrivatePlacementMember MAIA:BlackSholesMethodMember 2025-02-24 2025-02-24 0001878313 MAIA:AffiliatedAndNonaffiliatedInvestorMember MAIA:TwoThousandTwentyOneEquityIncentivePlanMember us-gaap:PrivatePlacementMember 2025-02-24 0001878313 MAIA:AffiliatedAndNonaffiliatedInvestorMember us-gaap:PrivatePlacementMember MAIA:BlackSholesMethodMember 2025-02-24 2025-02-24 0001878313 srt:DirectorMember MAIA:TwoThousandTwentyOneEquityIncentivePlanMember us-gaap:PrivatePlacementMember 2025-03-03 0001878313 srt:DirectorMember us-gaap:PrivatePlacementMember MAIA:BlackSholesMethodMember 2025-03-03 0001878313 srt:DirectorMember us-gaap:PrivatePlacementMember MAIA:BlackSholesMethodMember 2025-03-03 2025-03-03 0001878313 MAIA:NonaffiliatedInvestorsMember MAIA:TwoThousandTwentyOneEquityIncentivePlanMember us-gaap:PrivatePlacementMember 2025-03-03 0001878313 MAIA:NonaffiliatedInvestorsMember us-gaap:PrivatePlacementMember MAIA:BlackSholesMethodMember 2025-03-03 2025-03-03 0001878313 MAIA:TwoThousandEighteenStockOptionPlanMember 2026-03-31 0001878313 MAIA:AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember 2026-03-31 0001878313 MAIA:TwoThousandTwentyOneEquityIncentivePlanMember 2022-08-01 0001878313 MAIA:TwoThousandTwentyOneEquityIncentivePlanMember 2023-05-25 2023-05-25 0001878313 MAIA:TwoThousandTwentyOneEquityIncentivePlanMember 2022-12-31 0001878313 MAIA:TwoThousandTwentyOneEquityIncentivePlanMember 2024-01-01 0001878313 MAIA:TwoThousandTwentyOneEquityIncentivePlanMember 2025-01-01 0001878313 MAIA:TwoThousandTwentyOneEquityIncentivePlanMember 2026-01-01 0001878313 MAIA:TwoThousandTwentyOneEquityIncentivePlanMember 2026-03-31 0001878313 srt:MaximumMember 2026-01-01 2026-03-31 0001878313 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001878313 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001878313 us-gaap:EmployeeStockOptionMember 2026-03-31 0001878313 us-gaap:PerformanceSharesMember MAIA:TwoThousandTwentyOneEquityIncentivePlanMember 2026-01-01 2026-03-31 0001878313 us-gaap:PerformanceSharesMember MAIA:TwoThousandTwentyOneEquityIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2026-01-01 2026-03-31 0001878313 us-gaap:PerformanceSharesMember MAIA:TwoThousandTwentyOneEquityIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2026-01-01 2026-03-31 0001878313 us-gaap:PerformanceSharesMember MAIA:TwoThousandTwentyOneEquityIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2026-03-31 0001878313 2025-01-01 2025-12-31 0001878313 2024-01-01 2024-12-31 0001878313 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001878313 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001878313 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001878313 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001878313 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001878313 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001878313 MAIA:AteganosineTHIOTherapeuticsIncMember MAIA:AmendedPatentAndTechnologyLicenseAgreementMember 2018-11-01 2018-11-30 0001878313 srt:MinimumMember MAIA:AteganosineTHIOTherapeuticsIncMember MAIA:AmendedPatentAndTechnologyLicenseAgreementMember 2018-11-01 2018-11-30 0001878313 srt:MaximumMember MAIA:AteganosineTHIOTherapeuticsIncMember MAIA:AmendedPatentAndTechnologyLicenseAgreementMember 2018-11-01 2018-11-30 0001878313 MAIA:UniversityOfTexasSouthwesternMember MAIA:AmendedPatentAndTechnologyLicenseAgreementMember 2026-01-01 2026-03-31 0001878313 srt:MinimumMember MAIA:NetSalesUptoOneBillionMember MAIA:AteganosineTHIOTherapeuticsIncMember MAIA:AmendedPatentAndTechnologyLicenseAgreementMember 2018-11-01 2018-11-30 0001878313 srt:MaximumMember MAIA:NetSalesUptoOneBillionMember MAIA:AteganosineTHIOTherapeuticsIncMember MAIA:AmendedPatentAndTechnologyLicenseAgreementMember 2018-11-01 2018-11-30 0001878313 srt:MinimumMember MAIA:NetSalesAboveOneBillionMember MAIA:AteganosineTHIOTherapeuticsIncMember MAIA:AmendedPatentAndTechnologyLicenseAgreementMember 2018-11-01 2018-11-30 0001878313 srt:MaximumMember MAIA:NetSalesAboveOneBillionMember MAIA:AteganosineTHIOTherapeuticsIncMember MAIA:AmendedPatentAndTechnologyLicenseAgreementMember 2018-11-01 2018-11-30 0001878313 MAIA:UniversityOfTexasSouthwesternMember MAIA:PatentAndTechnologyLicenseAgreementMember 2020-12-01 2020-12-31 0001878313 srt:MinimumMember MAIA:UniversityOfTexasSouthwesternMember MAIA:PatentAndTechnologyLicenseAgreementMember 2020-12-01 2020-12-31 0001878313 srt:MaximumMember MAIA:UniversityOfTexasSouthwesternMember MAIA:PatentAndTechnologyLicenseAgreementMember 2020-12-01 2020-12-31 0001878313 srt:MinimumMember MAIA:NetSalesUptoOneBillionMember MAIA:UniversityOfTexasSouthwesternMember MAIA:PatentAndTechnologyLicenseAgreementMember 2020-12-01 2020-12-31 0001878313 srt:MaximumMember MAIA:NetSalesUptoOneBillionMember MAIA:UniversityOfTexasSouthwesternMember MAIA:PatentAndTechnologyLicenseAgreementMember 2020-12-01 2020-12-31 0001878313 srt:MinimumMember MAIA:NetSalesAboveOneBillionMember MAIA:UniversityOfTexasSouthwesternMember MAIA:PatentAndTechnologyLicenseAgreementMember 2020-12-01 2020-12-31 0001878313 srt:MaximumMember MAIA:NetSalesAboveOneBillionMember MAIA:UniversityOfTexasSouthwesternMember MAIA:PatentAndTechnologyLicenseAgreementMember 2020-12-01 2020-12-31 0001878313 MAIA:UniversityOfTexasSouthwesternMember MAIA:PatentAndTechnologyLicenseAgreementMember 2026-01-01 2026-03-31 0001878313 MAIA:RegeneronPharmaceuticalsIncMember 2021-02-01 2021-02-28 0001878313 MAIA:BeiGeneSwizerlandGmbHMember 2024-12-01 2024-12-31 0001878313 MAIA:EmployeesAndConsultantsMember us-gaap:SubsequentEventMember 2026-04-01 2026-05-11 0001878313 us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember MAIA:MasterServicesAgreementMember 2026-04-10 2026-04-10 0001878313 us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember MAIA:MasterServicesAgreementMember 2026-04-10 0001878313 us-gaap:RestrictedStockMember MAIA:FGMKBusinessHoldingsLLCMember us-gaap:SubsequentEventMember 2026-04-10 2026-04-10 0001878313 us-gaap:RestrictedStockMember MAIA:FGMKBusinessHoldingsLLCMember us-gaap:SubsequentEventMember 2026-04-10 0001878313 us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember MAIA:ResearchAndDevelopmentServicesMember 2026-04-10 2026-04-10 0001878313 us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember MAIA:ResearchAndDevelopmentServicesMember 2026-04-10 iso4217:USD shares iso4217:USD shares pure MAIA:Integer false Q1 --12-31 0001878313

10-Q true 2026-03-31 2026 false 001-41455 MAIA BIOTECHNOLOGY, INC. DE 83-1495913 444 West Lake Street Suite 1700 Chicago IL 60606 (312) 416-8592 Common Stock, $0.0001 par value per share MAIA NYSEAMER Yes Yes Non-accelerated Filer true true false false 60800758 0.0001

34413110

8658031

902017

1043825

35315127

9701856

7518

2800

35322645

9704656

2983058

2038803

3339379

3797595

6322437

5836398

1237440

1492395

7559877

7328793

0.0001

30000000

0.0001

150000000

60671491

38624289

6068

3863

143797024

112053233

-116000657

-109631005

-39667

-50228

27762768

2375863

35322645

9704656

3525097

3197532

3424832

2227899

6949929

5425431

-6949929

-5425431

111757

82183

213565

-254955

-825989

580277

908172

-6369652

-4517259

-0.14

-0.16

45212103

27696550

-6369652

-4517259

10561

-7540

-6359091

-4524799

38624289

3863

112053233

-109631005

-50228

2375863

21479

38547

38549

650024

19848

43649

43651

1995041

22005875 2201 31011571 31013772

10561

-6369652

60671491

6068

143797024

-116000657

-39667

27762768

26157788

2616

90897468

-87234833

-30615

3634636

26157788

2616

90897468

-87234833

-30615

3634636

570

844

371472

130220

666323

1390804

1390871

74448

2762633

276

2390457

2390733

1678768

-7540

-4517259

29587314

2959

96729813

-91752092

-38155

4942525

29587314

2959

96729813

-91752092

-38155

4942525

-6369652

-4517259

650024

371472

43651

-254955

-825989

-137114

456752

940877

359070

-458387

867184

-5311328

-4202274

38549

844

2715000

1428949

33008813

1521091

1995041

204668

31052321

5461216

14086

3056

25755079

1261998

8658031

9601298

34413110

10863296

1107202 571566

<p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zshWgGirW3P9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">1. NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business, Organization, and Principles of Consolidation MAIA Biotechnology, Inc. and subsidiaries (collectively, “the Company”) is a biopharmaceutical company that develops oncology drug candidates to improve and extend the lives of people with cancer. MAIA Biotechnology, Inc. (“MAIA”) was incorporated in the state of Delaware on August 3, 2018. These condensed consolidated financial statements include the accounts of MAIA and its subsidiaries, as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In July 2021, the Company established a wholly owned Australian subsidiary, MAIA Biotechnology Australia Pty Ltd., to conduct various pre-clinical and clinical activities for the development of the Company’s product candidates.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In April 2022, the Company established a wholly owned Romanian subsidiary, MAIA Biotechnology Romania S.R.L., to conduct various pre-clinical and clinical activities for the development of the Company’s product candidates.</td></tr> </table> Liquidity At March 31, 2026, the Company had working capital of $28,992,690, an accumulated deficit of $116,000,657, cash of $34,413,110 and current liabilities of $6,322,437. Since its inception the Company has experienced net losses and negative cash flows from operations each fiscal year. The Company has no revenue and expects to continue to incur operating losses for the foreseeable future and may never become profitable. The Company is dependent on its ability to continue to raise equity and/or debt financing to continue operations, and the attainment of profitable operations. Basis of Presentation and Consolidation Principles The accompanying condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements may not include all disclosures required by GAAP; however, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the fiscal year ended December 31, 2025, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 23, 2026. The condensed consolidated balance sheet as of December 31, 2025, was derived from such audited financial statements. In the opinion of management, all adjustments, consisting of only normal recurring adjustments that are necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, have been made. The results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods. The unaudited interim condensed consolidated financial statements include the accounts of the Company’s wholly owned subsidiaries. All transactions and accounts between and among its subsidiaries have been eliminated. All adjustments and disclosures necessary for a fair presentation of these unaudited interim condensed consolidated financial statements have been included. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker (“CODM”) in deciding how to allocate resources and assess performance. The Company and the Company’s chief operating decision-maker, the Company’s Chief Executive Officer, view the Company’s operations and manage its business as a single operating segment, which is the business of discovering and developing products for the treatment of immunotherapies for cancer. Management has determined that the Company operates in one segment, given the common nature of its operations. For additional information, see Note 8 - Segment Information. Use of Estimates The preparation of the Company’s unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the valuation of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), stock options and warrants, the embedded features in convertible notes, and accruals for outsourced research and development activities. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. Certain Risks and Uncertainties The Company’s activities are subject to significant risks and uncertainties, including the risk of failure to secure additional funding to properly execute the Company’s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, the development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements. Foreign Currency Translation The financial statements of the Company’s foreign subsidiaries, where the local currency is the functional currency, are translated using exchange rates in effect as of the applicable balance sheet dates for assets and liabilities and average exchange rates during the period for results of operations. The resulting foreign currency translation adjustment is included in stockholders’ equity as accumulated other comprehensive loss. Off-Balance Sheet Risk and Concentrations of Credit Risk The Company has no significant off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Cash accounts are maintained at financial institutions that potentially subject the Company to concentrations of credit risk. As of March 31, 2026 and December 31, 2025, substantially all of the Company’s cash was deposited in accounts at two financial institutions. The Company maintains its cash deposits, which at times may exceed the federally insured limits, with a reputable financial institution, and accordingly, the Company believes such funds are subject to minimal credit risk. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents. As of March 31, 2026, and December 31, 2025, the Company had no cash equivalents. Fair Value Measurements The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures (“ASC 820”) establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 - Valuations based on quoted prices for identical assets and liabilities in active markets.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</td></tr> </table> Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the three months ended March 31, 2026, and as of and during the twelve months ended December 31, 2025. The carrying amount of accounts payable approximated fair value, as they are short term in nature. The fair value of warrants issued for services is estimated based on the Black-Scholes-Merton model during the three months ended March 31, 2026. The estimated fair value of warrants issued to underwriters represented Level 3 measurements. General and Administrative General and administrative expenses primarily consist of costs for corporate functions, including payroll and related expenses, rent, outside legal expenses, insurance costs, and other general and administrative costs. Research and Development The Company’s research and development expenses consist primarily of costs associated with the Company’s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received. As part of the process of preparing the condensed consolidated financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company’s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in our condensed consolidated financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The estimates in the Company’s accrued research and development expenses are related to expenses incurred with respect to contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”), and other vendors in connection with research and development and manufacturing activities. The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company’s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company’s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented. Research and Development Incentive The Company recognizes other income from Australian research and development incentives when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The research and development incentive is one of the key elements of the Australian government’s support for Australia’s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997, as long as eligibility criteria are met. Under the program, a percentage of eligible research and development expenses incurred by the Company through its subsidiary in Australia are reimbursed. Management has assessed the Company’s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive regime described above. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time, and it is included in Australian research and development incentives in the condensed consolidated statements of operations. National Institute of Health (NIH) Grant The Company entered into an agreement with the National Cancer Institute for SBIR grant. Under the terms of the agreement, the National Cancer Institute has committed to reimburse the Company up to $2,297,863 of qualifying research and development expenses over the term of the grant. The Company’s ability to receive these funds is contingent upon incurring eligible costs and achieving certain performance objectives. Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period. Stock-Based Compensation The Company records share-based compensation for awards granted to employees, non-employees, and to members of the board of directors based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur. The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options and warrants. The use of the Black-Scholes-Merton option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. The Company has concluded that its historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company specific historical and implied volatility data, the estimate of expected volatility is primarily based on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the share-based awards, are selected. The Company computes the historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of its share-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of its Common Stock. All stock-based compensation costs are recorded in general and administrative or research and development costs in the condensed consolidated statements of operations based upon the underlying individual’s role at the Company. Common Stock Warrants The Company accounts for Common Stock warrants as either equity instruments or as liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), depending on the specific terms of the warrant agreement. When warrants are issued for services provided by non-employees, under ASC 718, Compensation – Stock Compensation (“ASC 718”), the warrants shall be classified as a liability if: (i) the underlying shares are classified as liabilities; or (ii) the entity can be required under any circumstances to settle the warrant by transferring cash or other assets. The measurement of equity-classified non-employee share-based payments is generally fixed on the grant date and are considered compensatory, as defined by ASC 718. Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized, assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. In July 2025, the One Big Beautiful Bill Act (Public Law 119-21) was enacted. The Company recognized the income tax effects of the legislation in the period of enactment in accordance with ASC 740. The legislation did not have a material impact on the Company’s consolidated financial statements for the quarter ended March 31, 2026. The Company will continue to evaluate the impact of the legislation on future periods. Recent Accounting Standards Effective January 1, 2025, the Company adopted ASU 2023-09, Improvements to Income Tax Disclosures, which expanded income tax disclosure requirements, including disaggregation of pretax income (loss) and income tax expense (benefit) by jurisdiction and disclosure of income taxes paid (net of refunds received). The adoption affected disclosures only and did not impact the Company’s financial position, results of operations, or cash flows. Net Loss Per Share Basic loss per share of Common Stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding for the period. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of Common Stock equivalents outstanding for the period, determined using the treasury-stock method. Diluted loss per share excludes, when applicable, the potential impact of stock options, unvested shares of restricted stock awards, and common stock warrants because their effect would be anti-dilutive due to our net loss. Gains on warrant liabilities are only considered dilutive when the average market price of the Common Stock during the period exceeds the exercise price of the warrants. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same. <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zcMhtU2O9lQe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">The following table summarizes the Company’s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive: SCHEDULE OF ANTIDILUTIVE SHARES EXCLUDED FROM CALCULATION OF DILUTIVE LOSS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260101__20260331_zEZ8vTYoZ3m3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20250331_zSkwyNQIqSU" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zFuhUoPTuAN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Shares issuable upon exercise of stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">13,097,991</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">10,904,814</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zjxJ4RbxMNb5" style="vertical-align: bottom; background-color: White"> <td>Shares issuable upon exercise of warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,086,220</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,299,143</td><td style="text-align: left"> </td></tr> </table> Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, as amended, Leases (“Topic 842”), which applies to all leases. Under Topic 842, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing leases, while the statement of operations will reflect lease expense for operating leases and amortization and interest expense for financing leases. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. All leases with a term greater than one year are recognized on the consolidated balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the consolidated balance sheet leases with terms of one year or less. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. Currently none of the Company’s operating lease commitments are subject to the standard as its leases are short-term in nature (i.e., less than twelve months). Recent Accounting Standards In March 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which requires detailed disclosure of significant expense components and additional clarity when expenses are classified by function. ASU No. 2024-03 is effective for fiscal years beginning after December 15, 2026 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. We do not expect the amendments in this ASU to have a material impact on our consolidated financial statements. In December 2025, the FASB issued ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities, which requires recognizing grants when compliance with conditions is probable. ASU 2025-10 is effective for fiscal years beginning after December 15, 2028 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. See Note 9 – Government Grants. From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

DE 2018-08-03 Liquidity At March 31, 2026, the Company had working capital of $28,992,690, an accumulated deficit of $116,000,657, cash of $34,413,110 and current liabilities of $6,322,437. Since its inception the Company has experienced net losses and negative cash flows from operations each fiscal year. The Company has no revenue and expects to continue to incur operating losses for the foreseeable future and may never become profitable. The Company is dependent on its ability to continue to raise equity and/or debt financing to continue operations, and the attainment of profitable operations. 28992690

-116000657

34413110

6322437

Basis of Presentation and Consolidation Principles The accompanying condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements may not include all disclosures required by GAAP; however, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the fiscal year ended December 31, 2025, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 23, 2026. The condensed consolidated balance sheet as of December 31, 2025, was derived from such audited financial statements. In the opinion of management, all adjustments, consisting of only normal recurring adjustments that are necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, have been made. The results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods. The unaudited interim condensed consolidated financial statements include the accounts of the Company’s wholly owned subsidiaries. All transactions and accounts between and among its subsidiaries have been eliminated. All adjustments and disclosures necessary for a fair presentation of these unaudited interim condensed consolidated financial statements have been included.

Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker (“CODM”) in deciding how to allocate resources and assess performance. The Company and the Company’s chief operating decision-maker, the Company’s Chief Executive Officer, view the Company’s operations and manage its business as a single operating segment, which is the business of discovering and developing products for the treatment of immunotherapies for cancer. Management has determined that the Company operates in one segment, given the common nature of its operations. For additional information, see Note 8 - Segment Information.

Use of Estimates The preparation of the Company’s unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the valuation of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), stock options and warrants, the embedded features in convertible notes, and accruals for outsourced research and development activities. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.

0.0001

Certain Risks and Uncertainties The Company’s activities are subject to significant risks and uncertainties, including the risk of failure to secure additional funding to properly execute the Company’s business plan. The Company is subject to risks that are common to companies in the pharmaceutical industry, including, but not limited to, the development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.

Foreign Currency Translation The financial statements of the Company’s foreign subsidiaries, where the local currency is the functional currency, are translated using exchange rates in effect as of the applicable balance sheet dates for assets and liabilities and average exchange rates during the period for results of operations. The resulting foreign currency translation adjustment is included in stockholders’ equity as accumulated other comprehensive loss.

Off-Balance Sheet Risk and Concentrations of Credit Risk The Company has no significant off-balance sheet risks, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Cash accounts are maintained at financial institutions that potentially subject the Company to concentrations of credit risk. As of March 31, 2026 and December 31, 2025, substantially all of the Company’s cash was deposited in accounts at two financial institutions. The Company maintains its cash deposits, which at times may exceed the federally insured limits, with a reputable financial institution, and accordingly, the Company believes such funds are subject to minimal credit risk.

Cash and Cash Equivalents The Company considers all highly liquid investments purchased with maturities of three months or less to be cash equivalents. As of March 31, 2026, and December 31, 2025, the Company had no cash equivalents.

Fair Value Measurements The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures (“ASC 820”) establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 - Valuations based on quoted prices for identical assets and liabilities in active markets.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</td></tr> </table> Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the three months ended March 31, 2026, and as of and during the twelve months ended December 31, 2025. The carrying amount of accounts payable approximated fair value, as they are short term in nature. The fair value of warrants issued for services is estimated based on the Black-Scholes-Merton model during the three months ended March 31, 2026. The estimated fair value of warrants issued to underwriters represented Level 3 measurements.

General and Administrative General and administrative expenses primarily consist of costs for corporate functions, including payroll and related expenses, rent, outside legal expenses, insurance costs, and other general and administrative costs.

Research and Development The Company’s research and development expenses consist primarily of costs associated with the Company’s clinical trials, salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in ongoing research and development efforts. Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received. As part of the process of preparing the condensed consolidated financial statements, the Company is required to estimate its accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company’s service providers invoice the Company monthly in arrears for services performed or when contractual milestones are met. The Company makes estimates of its accrued expenses as of each balance sheet date in our condensed consolidated financial statements based on facts and circumstances known to the Company at that time. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. The estimates in the Company’s accrued research and development expenses are related to expenses incurred with respect to contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”), and other vendors in connection with research and development and manufacturing activities. The Company bases its expense related to CROs and CMOs on its estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on the Company’s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from its estimate, the Company adjusts the accrual or prepaid expense accordingly. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company’s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.

Research and Development Incentive The Company recognizes other income from Australian research and development incentives when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The research and development incentive is one of the key elements of the Australian government’s support for Australia’s innovation system and is supported by legislative law primarily in the form of the Australian Income Tax Assessment Act 1997, as long as eligibility criteria are met. Under the program, a percentage of eligible research and development expenses incurred by the Company through its subsidiary in Australia are reimbursed. Management has assessed the Company’s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive regime described above. At each period end, management estimates the refundable tax offset available to the Company based on available information at the time, and it is included in Australian research and development incentives in the condensed consolidated statements of operations.

National Institute of Health (NIH) Grant The Company entered into an agreement with the National Cancer Institute for SBIR grant. Under the terms of the agreement, the National Cancer Institute has committed to reimburse the Company up to $2,297,863 of qualifying research and development expenses over the term of the grant. The Company’s ability to receive these funds is contingent upon incurring eligible costs and achieving certain performance objectives.

2297863

Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period.

Stock-Based Compensation The Company records share-based compensation for awards granted to employees, non-employees, and to members of the board of directors based on the grant date fair value of awards issued, and the expense is recorded on a straight-line basis over the requisite service period. Forfeitures are recognized when they occur. The Company uses the Black-Scholes-Merton option pricing model to determine the fair value of stock options and warrants. The use of the Black-Scholes-Merton option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. The Company has concluded that its historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. Therefore, the expected term was determined according to the simplified method, which is the average of the vesting tranche dates and the contractual term. Due to the lack of company specific historical and implied volatility data, the estimate of expected volatility is primarily based on the historical volatility of a group of similar companies that are publicly traded. For these analyses, companies with comparable characteristics, including enterprise value and position within the industry, and with historical share price information sufficient to meet the expected life of the share-based awards, are selected. The Company computes the historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of its share-based awards. The risk-free interest rate is determined by reference to U.S. Treasury zero-coupon issues with remaining maturities similar to the expected term of the options. The Company has not paid, and does not anticipate paying, cash dividends on shares of its Common Stock. All stock-based compensation costs are recorded in general and administrative or research and development costs in the condensed consolidated statements of operations based upon the underlying individual’s role at the Company.

Common Stock Warrants The Company accounts for Common Stock warrants as either equity instruments or as liabilities in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), depending on the specific terms of the warrant agreement. When warrants are issued for services provided by non-employees, under ASC 718, Compensation – Stock Compensation (“ASC 718”), the warrants shall be classified as a liability if: (i) the underlying shares are classified as liabilities; or (ii) the entity can be required under any circumstances to settle the warrant by transferring cash or other assets. The measurement of equity-classified non-employee share-based payments is generally fixed on the grant date and are considered compensatory, as defined by ASC 718.

Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized, assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. In July 2025, the One Big Beautiful Bill Act (Public Law 119-21) was enacted. The Company recognized the income tax effects of the legislation in the period of enactment in accordance with ASC 740. The legislation did not have a material impact on the Company’s consolidated financial statements for the quarter ended March 31, 2026. The Company will continue to evaluate the impact of the legislation on future periods.

Recent Accounting Standards Effective January 1, 2025, the Company adopted ASU 2023-09, Improvements to Income Tax Disclosures, which expanded income tax disclosure requirements, including disaggregation of pretax income (loss) and income tax expense (benefit) by jurisdiction and disclosure of income taxes paid (net of refunds received). The adoption affected disclosures only and did not impact the Company’s financial position, results of operations, or cash flows.

Net Loss Per Share Basic loss per share of Common Stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding for the period. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of Common Stock equivalents outstanding for the period, determined using the treasury-stock method. Diluted loss per share excludes, when applicable, the potential impact of stock options, unvested shares of restricted stock awards, and common stock warrants because their effect would be anti-dilutive due to our net loss. Gains on warrant liabilities are only considered dilutive when the average market price of the Common Stock during the period exceeds the exercise price of the warrants. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same. <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zcMhtU2O9lQe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">The following table summarizes the Company’s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive: SCHEDULE OF ANTIDILUTIVE SHARES EXCLUDED FROM CALCULATION OF DILUTIVE LOSS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260101__20260331_zEZ8vTYoZ3m3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20250331_zSkwyNQIqSU" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zFuhUoPTuAN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Shares issuable upon exercise of stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">13,097,991</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">10,904,814</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zjxJ4RbxMNb5" style="vertical-align: bottom; background-color: White"> <td>Shares issuable upon exercise of warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,086,220</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,299,143</td><td style="text-align: left"> </td></tr> </table>

<p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zcMhtU2O9lQe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">The following table summarizes the Company’s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive: SCHEDULE OF ANTIDILUTIVE SHARES EXCLUDED FROM CALCULATION OF DILUTIVE LOSS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260101__20260331_zEZ8vTYoZ3m3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20250331_zSkwyNQIqSU" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zFuhUoPTuAN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Shares issuable upon exercise of stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">13,097,991</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">10,904,814</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zjxJ4RbxMNb5" style="vertical-align: bottom; background-color: White"> <td>Shares issuable upon exercise of warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,086,220</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,299,143</td><td style="text-align: left"> </td></tr> </table>

13097991

10904814

13086220

9299143

Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, as amended, Leases (“Topic 842”), which applies to all leases. Under Topic 842, a right-of-use asset and lease obligation will be recorded for all leases, whether operating or financing leases, while the statement of operations will reflect lease expense for operating leases and amortization and interest expense for financing leases. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. All leases with a term greater than one year are recognized on the consolidated balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the consolidated balance sheet leases with terms of one year or less. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. At the inception of an arrangement the Company determines whether the arrangement is or contains a lease based on the circumstances present. Currently none of the Company’s operating lease commitments are subject to the standard as its leases are short-term in nature (i.e., less than twelve months).

Recent Accounting Standards In March 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which requires detailed disclosure of significant expense components and additional clarity when expenses are classified by function. ASU No. 2024-03 is effective for fiscal years beginning after December 15, 2026 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. We do not expect the amendments in this ASU to have a material impact on our consolidated financial statements. In December 2025, the FASB issued ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities, which requires recognizing grants when compliance with conditions is probable. ASU 2025-10 is effective for fiscal years beginning after December 15, 2028 and allows for adoption on a prospective basis, with a retrospective option. Early adoption is permitted. See Note 9 – Government Grants. From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

2. RELATED PARTY TRANSACTIONS Consulting Services and Private Placement The consulting firm FGMK, LLC and its affiliate FGMK Business Holdings, LLC beneficially own more than <span id="xdx_90D_ecustom--PercentageOfStockOwned_dp_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FGMKLLCAndFGMKBusinessHoldingsLLCMember__srt--RangeAxis__srt--MinimumMember_zRZzMimn3lc8" title="Percentage of stock owned">5% of the stock of the Company and are therefore related parties. The Company expensed $<span id="xdx_900_eus-gaap--ProfessionalFees_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FGMKLLCAndFGMKBusinessHoldingsLLCMember_zZprPi2dTXI3" title="Accounting, tax and valuation services expense">0 and $<span id="xdx_901_eus-gaap--ProfessionalFees_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FGMKLLCAndFGMKBusinessHoldingsLLCMember_zgi18oZVszhc" title="Accounting, tax and valuation services expense">11,445 during the three month period ended March 31, 2026 and March 31, 2025, respectively, related to accounting, tax and valuation services provided by these parties. In addition, FGMK Business Holdings, LLC participated in the February 2025 private placement and purchased <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250201__20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FGMKBusinessHoldingsLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zslqPJdZMw87" title="Number of common stock Issued and sold">1,350,000 shares of the Company’s Common Stock and warrants to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20250228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FGMKBusinessHoldingsLLCMember_zBVSDxaQhNRf" title="Warrants to purchase common stock">1,350,000 shares of the Company’s Common Stock for an aggregate purchase price of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250201__20250228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FGMKBusinessHoldingsLLCMember_zKdUNgbhBKHk" title="Aggregate purchase price">2,025,000. 10b5-1 Plan Certain of our directors and executive officers previously adopted written plans, known as Rule 10b5-1 plans, in which they contracted with a broker to buy shares of our Common Stock on a periodic basis. Each of these plans have expired as of the date of this Quarterly Report. Our directors and executive officers may, in the future, adopt Rule 10b5-1 plans in which they contract with a broker to buy or sell shares of our Common Stock on a periodic basis. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the director or officer at the time it was entered into, without further direction from the director or officer. The director or officer may amend or terminate the plan in limited circumstances. Our directors and executive officers may also buy or sell additional shares of our Common Stock outside of a Rule 10b5-1 plan when they are not in possession of material non-public information. Private Placement The following Company directors participated in the February 2025 private placement as follows: (i) Stan Smith purchased <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250201__20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StanSmithMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zg7CqzjaXto" title="Issuance of shares">50,000 shares of our Common Stock and warrants to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StanSmithMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zA2ksgkK9qT9" title="Issuance of warrants">50,000 shares of our Common Stock for an aggregate purchase price of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250201__20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StanSmithMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zVqGhBN7Rqk4" title="Issuance of private placement">75,000; (ii) Ramiro Guerrero purchased <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250201__20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RamiroGuerreroMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z0r6GGWz4dL4" title="Issuance of shares">73,333 shares of our Common Stock and warrants to purchase up to <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RamiroGuerreroMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zPZmvC2W5h4c" title="Issuance of warrants">73,333 shares of our Common Stock for an aggregate purchase price of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250201__20250228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RamiroGuerreroMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zz9kSBcRocOg" title="Issuance of private placement">110,000. The following Company directors participated in the March 2025 private placement as follows: (i) Stan Smith purchased <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250301__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StanSmithMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zihFZbBfljJj" title="Issuance of shares">25,000 shares of our Common Stock and warrants to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StanSmithMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zKM0vYJyvFwi" title="Issuance of warrants">25,000 shares of our Common Stock for an aggregate purchase price of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250301__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StanSmithMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGap6pV9UuXj" title="Issuance of private placement">37,500; (ii) Ramiro Guerrero purchased <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250301__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RamiroGuerreroMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zJwzMI7VAtT6" title="Numbert of common stock issued">33,333 shares of our Common Stock and warrants to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RamiroGuerreroMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zLqcqumGP26f" title="Warrants issued to purchase common stock">33,333 shares of our Common Stock for an aggregate purchase price of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250301__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RamiroGuerreroMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zi1zol9Id908" title="Aggregate purchase price">50,000. There were no private placements in the quarter ended March 31, 2026.

0.05

11445

1350000

2025000

50000

75000

73333

110000

25000

37500

33333

50000

3. ACCRUED EXPENSES As of March 31, 2026 and December 31, 2025 accrued expenses consisted of the following: SCHEDULE OF ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20260331_z4ASsZs0s0Vd" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20251231_zEwMxIDtyla" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedBonusesCurrent_iI_maALCzmwg_zEFCwH0U4MQb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Bonus</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,508,892</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,199,955</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzmwg_zlpTlGQKoE55" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">195,650</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">288,077</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--AccruedResearchAndDevelopmentCostsCurrent_iI_maALCzmwg_z3cINRl6hoj6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,309,175</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,061,497</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzmwg_z55xULNF5Sza" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">325,662</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">248,066</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzmwg_zwLpvDoTXgG4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,339,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,797,595</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

As of March 31, 2026 and December 31, 2025 accrued expenses consisted of the following: SCHEDULE OF ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20260331_z4ASsZs0s0Vd" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20251231_zEwMxIDtyla" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedBonusesCurrent_iI_maALCzmwg_zEFCwH0U4MQb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Bonus</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,508,892</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,199,955</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzmwg_zlpTlGQKoE55" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">195,650</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">288,077</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--AccruedResearchAndDevelopmentCostsCurrent_iI_maALCzmwg_z3cINRl6hoj6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,309,175</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,061,497</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzmwg_z55xULNF5Sza" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">325,662</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">248,066</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzmwg_zwLpvDoTXgG4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,339,379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,797,595</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1508892

1199955

195650

288077

1309175 2061497

325662

248066

3339379

3797595

4. FAIR VALUE OF FINANCIAL LIABILITIES Derivative Liability Financial liabilities consisting of warrant liabilities measured at fair value on a recurring basis are summarized below. The fair value of the warrant liabilities recorded are as follows: SCHEDULE OF FAIR VALUE MEASUREMENT OF EMBEDDED DERIVATIVE LIABILITIES AND WARRANT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value at March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zBs36HbRNPm1" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Warrant liability">1,237,440</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zP352siDRCy2" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Warrant liability">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zidLjkohgZi3" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Warrant liability">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zewRIaW289K6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Warrant liability">1,237,440</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGlcncz1dJ16" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities">1,237,440</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeuu0eLNHfJ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zG726uS9bZPc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkelwpnviQM7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities">1,237,440</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value at December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zNyIk7YkM898" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Warrant liability">1,492,395</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z0hHm5XIEU8" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Warrant liability">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zH66P2GPq3u1" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Warrant liability">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDRejr5biKil" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Warrant liability">1,492,395</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z1njPNs6UtQl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities">1,492,395</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJdGen4V1wia" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYpZLrBdspHb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zq8QjLNtLTHc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities">1,492,395</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The table below provides a summary of the changes in fair value of the warrant liabilities measured on a recurring basis using significant unobservable inputs (Level 3): <p id="xdx_896_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zRaeSIhwCi32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"> SCHEDULE OF CHANGES IN FAIR VALUE OF THE DERIVATIVE LIABILITIES AND WARRANT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260101__20260331_zfTZcoQLyff8" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">2026</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20250101__20250331_zPYwPkIGI69d" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended March 31,</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"></td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Warrant liability:</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_403_eus-gaap--WarrantsAndRightsOutstanding_iS_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zF8XKRzDndfk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 62%">Balance, beginning of period</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,492,395</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">2,690,605</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfWarrants_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zJJ88MhIAGcb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Issuance of warrants</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_400_eus-gaap--ProceedsFromWarrantExercises_iN_di_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zbZOh6Jyt2K3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Exercise of warrants</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40D_eus-gaap--AdjustmentOfWarrantsGrantedForServices_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZaxeqwe8SUg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Amendment of warrants</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_402_eus-gaap--FairValueAdjustmentOfWarrants_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z4JAcs8iH0Fi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Gain on fair value of warrant liability</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(254,955)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(825,989</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td></tr> <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstanding_iE_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zrKOuCsS4VZ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, end of period</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,237,440</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,864,616</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

Financial liabilities consisting of warrant liabilities measured at fair value on a recurring basis are summarized below. The fair value of the warrant liabilities recorded are as follows: SCHEDULE OF FAIR VALUE MEASUREMENT OF EMBEDDED DERIVATIVE LIABILITIES AND WARRANT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value at March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zBs36HbRNPm1" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Warrant liability">1,237,440</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zP352siDRCy2" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Warrant liability">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zidLjkohgZi3" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Warrant liability">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zewRIaW289K6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Warrant liability">1,237,440</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zGlcncz1dJ16" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities">1,237,440</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeuu0eLNHfJ4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zG726uS9bZPc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkelwpnviQM7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities">1,237,440</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value at December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zNyIk7YkM898" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Warrant liability">1,492,395</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z0hHm5XIEU8" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Warrant liability">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zH66P2GPq3u1" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Warrant liability">—</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDRejr5biKil" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Warrant liability">1,492,395</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z1njPNs6UtQl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities">1,492,395</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJdGen4V1wia" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYpZLrBdspHb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zq8QjLNtLTHc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities">1,492,395</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1237440

1492395

<p id="xdx_896_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zRaeSIhwCi32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"> SCHEDULE OF CHANGES IN FAIR VALUE OF THE DERIVATIVE LIABILITIES AND WARRANT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260101__20260331_zfTZcoQLyff8" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">2026</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20250101__20250331_zPYwPkIGI69d" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended March 31,</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"></td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Warrant liability:</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_403_eus-gaap--WarrantsAndRightsOutstanding_iS_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zF8XKRzDndfk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 62%">Balance, beginning of period</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,492,395</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">2,690,605</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfWarrants_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zJJ88MhIAGcb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Issuance of warrants</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_400_eus-gaap--ProceedsFromWarrantExercises_iN_di_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zbZOh6Jyt2K3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Exercise of warrants</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_40D_eus-gaap--AdjustmentOfWarrantsGrantedForServices_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZaxeqwe8SUg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Amendment of warrants</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_402_eus-gaap--FairValueAdjustmentOfWarrants_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z4JAcs8iH0Fi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Gain on fair value of warrant liability</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(254,955)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(825,989</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td></tr> <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstanding_iE_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zrKOuCsS4VZ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, end of period</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,237,440</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,864,616</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

1492395

2690605

-254955

-825989

1237440

1864616

5. STOCKHOLDERS’ EQUITY Upon the closing of the Company’s July 2022 initial public offering (“IPO”), the Company’s shareholders agreement terminated pursuant to its terms. In connection with the closing of the IPO, the Company amended and restated its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”) and amended and restated its Bylaws (the “Amended and Restated Bylaws”). The Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on August 1, 2022, and became effective on that date, and among other things, increased the authorized number of Common Stock to 70,000,000 shares and decreased the authorized number of Preferred Stock to 30,000,000 shares. On May 22, 2025 the Company’s shareholders approved an amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 70,000,000 to 150,000,000. The Certificate of Amendment was filed with the Secretary of State of the State of Delaware on May 22, 2025, and became effective on that date, increasing the authorized number of shares of Common Stock to 150,000,000. The number of shares of Preferred Stock authorized remains 30,000,000 shares. At-the-Market Equity Offering On February 14, 2024, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), to sell shares of its Common Stock, par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240214__srt--CounterpartyNameAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingAgreementMember_zhrtohQyd0h3" title="Common stock, par value">0.0001 per share, (the “Shares”) having an aggregate sales price of up to $<span id="xdx_907_ecustom--AggregateOfferingPriceUnderSalesAgreement_iI_c20240214__srt--CounterpartyNameAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingAgreementMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcgiMgG6aoVk" title="Aggregate offering price">1,445,000, from time to time, through an at-the-market offering program under which Wainwright will act as sales agent. The sales, if any, of the Shares made under the ATM Agreement will be made by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Effective March 25, 2024, the Company filed a prospectus supplement to amend, supplement and supersede certain information contained in the earlier prospectus and prospectus supplement, which increased the number of Shares the Company may offer and sell under the ATM Agreement to an aggregate offering price of up to $<span id="xdx_90B_ecustom--AggregateOfferingPriceUnderSalesAgreement_iI_c20240325__srt--CounterpartyNameAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingAgreementMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrrsR4V2k1y6" title="Aggregate offering price">4,950,000, from time to time, which did not include any sales made previously under the ATM Agreement. Effective December 23, 2024, the Company filed a prospectus supplement to amend, supplement and supersede certain information contained in the earlier prospectus and prospectus supplement, which increased the number of Shares the Company may offer and sell under the ATM Agreement to an aggregate offering price of up to $<span id="xdx_90E_ecustom--AggregateOfferingPriceUnderSalesAgreement_iI_c20241223__srt--CounterpartyNameAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingAgreementMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOSUUNfilEQl" title="Aggregate offering price">30,000,000 from time to time. Effective March 22, 2025, the Company filed a prospectus supplement to amend, supplement and supersede certain information contained in the earlier prospectus and prospectus supplement, which decreased the number of Shares the Company may offer and sell under the ATM Agreement to an aggregate offering price of up to $<span id="xdx_906_ecustom--AggregateOfferingPriceUnderSalesAgreement_iI_c20250322__srt--CounterpartyNameAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingAgreementMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3zVpvKcJJ2k" title="Aggregate offering price">11,200,000 from time to time, which did not include any sales made previously under the ATM Agreement. During the quarter ended March 31, 2025, the Company sold <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250101__20250331__srt--CounterpartyNameAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingAgreementMember_z3O2hZ2dRaw3" title="Number of common stock sold">666,323 shares of Common Stock at an average price of approximately $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250331__srt--CounterpartyNameAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingAgreementMember_z6wqCeRGXtIa" title="Common stock per share">2.28 per share, resulting in aggregate gross proceeds of approximately $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250101__20250331__srt--CounterpartyNameAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingAgreementMember_ziADQHtUnOFa" title="Gross proceeds from offering">1,521,091, for which it paid Wainwright approximately $<span id="xdx_906_ecustom--SalesAgentCommissions_c20250101__20250331__srt--CounterpartyNameAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingAgreementMember_zxT3Nn2Wtwg2" title="Commissions paid">45,633 in commissions and other issuance costs of $<span id="xdx_903_eus-gaap--PaymentsOfStockIssuanceCosts_c20250101__20250331__srt--CounterpartyNameAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingAgreementMember_ziioHyPfxzPe" title="Issuance costs">84,587, resulting in net proceeds to the Company of approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20250101__20250331__srt--CounterpartyNameAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketOfferingAgreementMember_zWiSKtKuU0y9" title="Net proceeds from offering">1,390,871. During the quarter ended March 31, 2026, the Company did not sell shares of Common Stock under the ATM agreement. Private Placement On February 24, 2025, the Company issued and sold <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250224__20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zKWRMOsBFU17" title="Number of common stock sold">1,810,000 shares of its Common Stock and warrants to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zkAsdc1iiNV8" title="Number of common stock sold">1,810,000 shares of its Common Stock in a private placement to certain accredited investors and Company directors pursuant to securities purchase agreements dated February 18, 2025 at a price per share of $1.50 for which the Company received gross proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20250224__20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zrqv5lblxEhd" title="Aggregate purchase price">2.7 million. The warrants are exercisable at a price per share of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zq6w0FvZbda6" title="Warrant exercise price">1.87, are exercisable commencing one year following issuance, have a term of six years from the issuance date, and expiring on February 24, 2031. The securities sold to Company directors participating in the private placement were issued pursuant to the MAIA Biotechnology, Inc. 2021 Equity Incentive Plan (the “MAIA 2021 Plan”). On March 3, 2025, the Company issued and sold <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250303__20250303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zMeM4GCN3Dyg" title="Number of common stock sold">952,633 shares of its Common Stock and warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zuqy8zx3Ea59" title="Number of common stock sold">952,633 shares of its Common Stock in a private placement to certain accredited investors and Company directors pursuant to securities purchase agreements dated February 25, 2025 at a price per share of $1.50 for which the Company received gross proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn4n6_c20250303__20250303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGDemsXPsboa" title="Gross proceeds from private placement">1.4 million. The warrants are exercisable at a price per share of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ztnF3WM8TYL" title="Warrant exercise price">1.85, are exercisable commencing one year following issuance, have a term of six years from the issuance date, and expiring on March 3, 2031. The securities sold to Company directors participating in the private placement were issued pursuant to the MAIA Biotechnology, Inc. 2021 Equity Incentive Plan (the “MAIA 2021 Plan”). There were no private placements in the quarter ended March 31, 2026. Confidentially Marketed Public Offering On March 4, 2026, the Company issued and sold <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20260304__20260304__us-gaap--SubsidiarySaleOfStockAxis__custom--ConfidentiallyMarketedPublicOfferingMember_zEiX1knH4kah" title="Number of common stock sold">20,000,000 shares of its Common Stock to certain accredited investors pursuant to a confidentially marketed public offering with Konik Capital Partners, LLC. (“Konik Capital”) at a price per share of $1.50 for which the Company received gross proceeds of approximately $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20260304__20260304__us-gaap--SubsidiarySaleOfStockAxis__custom--ConfidentiallyMarketedPublicOfferingMember_zOSZDiZBgkBg" title="Aggregate purchase price">30,000,000. The Company paid Konik Capital approximately $1,500,000 in commissions and other issuance costs of approximately $329,000, resulting in net proceeds to the Company of approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__custom--ConfidentiallyMarketedPublicOfferingMember_zCUl8VeKoOOi" title="Net proceeds from offering">28,171,000. On March 9, 2026, the Company issued and sold <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20260309__20260309__us-gaap--SubsidiarySaleOfStockAxis__custom--ConfidentiallyMarketedPublicOfferingMember_zBRv8daBvfTd" title="Number of common stock sold">2,005,875 shares of its Common Stock to certain accredited investors pursuant to a confidentially marketed follow-on public offering with Konik Capital at a price per share of $1.50 for which the Company received gross proceeds of approximately $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20260309__20260309__us-gaap--SubsidiarySaleOfStockAxis__custom--ConfidentiallyMarketedPublicOfferingMember_z2RJxQPV9kte" title="Gross proceeds from offering">3,009,000. The Company paid Konik Capital approximately $150,000 in commissions and other issuance costs of approximately $16,000, resulting in net proceeds to the Company of approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20260309__20260309__us-gaap--SubsidiarySaleOfStockAxis__custom--ConfidentiallyMarketedPublicOfferingMember_zQ6tKcbdHoYf" title="Net proceeds from offering">2,843,000. MAIA Biotechnology, Inc. Restricted Stock Awards During the three months ended March 31, 2026, the Company expensed $43,651 to research and development expense for research services that were performed in exchange for the grant of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zDxzZmsqF5yb" title="Restricted shares granted">19,848 restricted shares. There are <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_do_c20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNBOPEtG3N49" title="Unvested restricted shares">no unvested restricted shares as of March 31, 2026. During the three months ended March 31, 2025, the Company had no expense related to restricted shares of Common Stock. There are <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_do_c20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKf93KzfKVde" title="Unvested restricted shares">no unvested restricted shares as of March 31, 2025. MAIA Stock Warrants Concurrently with the closing of the IPO, the Company issued warrants to purchase an aggregate of up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zRq5KwCQ8If8" title="Warrants to purchase aggregate of common stock">100,000 shares of its Common Stock to the representative or its designees, at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z5hmLIPSB0Rk" title="Warrants exercise price, per share">6.25 per share (the “Representative’s Warrants”). The Representative’s Warrants were exercisable beginning on <span id="xdx_909_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20220801__20220801__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zwuE8JEl7iO7" title="Warrants and rights exercisable period">January 23, 2023, and expire on July 27, 2027, pursuant to their terms and conditions. On August 3, 2023, concurrently with the full exercise of the representative’s over-allotment option, the Company issued additional Representative’s Warrants to purchase an aggregate of up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220803__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zCg3mXNDVtFb" title="Warrants to purchase aggregate of common stock">15,000 shares of its Common Stock to the representative or its designees on the same terms. The Representative’s Warrants are not indexed to the Company’s own stock and therefore meet the definition of a derivative liability. The Representative’s Warrants are liability classified instruments and were initially recorded at a value of $343,735, which was determined using the Black-Scholes-Merton method using a term of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dc_c20220803__20220803__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zI9byjBZOxI6" title="Fair value assumptions, contractual term">five years, risk free interest rate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220803__20220803__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zIy9v9eob5W2" title="Risk free interest rate">2.82% and volatility of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220803__20220803__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zV0vKk89P931" title="Volatility rate">77.5%. As of March 31, 2026 and December 31, 2025, the Company remeasured the warrant liability resulting in a value of $<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstanding_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zXE7hpzDZqi6" title="Warrant liability">4,324 and $<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstanding_iI_c20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zCrZEiCv7DR4" title="Warrant liability">27,455 respectively. The gain on remeasurement of the warrant liability in the amount of $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zE5CPP3IyTJ" title="Change in fair value of warrant liability">23,131 and $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zttmEl2e9qai" title="Change in fair value of warrant liability">26,268 was included in other income (expense) for the three months ended March 31, 2026 and March 31, 2025 respectively. On November 17, 2023, the Company issued warrants concurrently with the Company’s registered direct offering to purchase an aggregate of up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231117__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_z3BBByWKEWRk" title="Warrants to purchase aggregate of common stock">2,424,243 shares of its Common Stock to the investors in the registered direct offering at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231117__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zXhmig3uQ2db" title="Warrants exercise price, per share">1.86 per share (subject to customary adjustments as set forth in the warrants). The warrants are exercisable six months following issuance and will have a term of five years from the initial exercise date. The warrants contain customary anti-dilution adjustments to the exercise price, including for share splits, share dividends, rights offerings and pro rata distributions. The warrants were not indexed to the Company’s own stock and therefore met the definition of a derivative liability. The warrants were liability classified instruments and were initially recorded at a value of $1,903,915, which was determined using the Black-Scholes-Merton method using a term of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231117__20231117__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zeP5KzU2B8Gd" title="Fair value assumptions, contractual term">5.38 years, risk free interest rate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20231117__20231117__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zQR3HHno25d1" title="Risk free interest rate">3.85% and volatility of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20231117__20231117__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_z57kAmY3UlNk" title="Volatility rate">90.0%. During the nine months ended September 30, 2024, 909,091 warrants were exercised on various dates in cashless exercises and the investor was issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20240930__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_znaxdg9bDup5" title="Number of common stock sold">458,726 shares of Common Stock. The Company remeasured the warrant liability of the exercised warrants at the time of the exercise resulting in a value of $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_c20231117__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zrkaqeVuIv73" title="Warrants">2,815,970. The warrant liability for the exercised warrants was removed and equity was increased by the value of $<span id="xdx_901_ecustom--IncreaseInEquityOnExerciseOfWarrantLiability_c20231117__20231117__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zuBZ2zRdYhE3" title="Increase in equity on exercise of warrant liability">2,815,970. As of March 31, 2026 and December 31, 2025, the warrant liability resulted in a value of $<span id="xdx_907_eus-gaap--WarrantsAndRightsOutstanding_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zAW0uPJ2ZAV8" title="Warrants">1,025,007 and $ <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstanding_iI_c20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_z3WcJOpJyLia" title="Warrants">1,216,774, respectively. The gain on remeasurement in the amount of $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_ztpnASB7rSu9" title="Change in fair value of warrant liability">191,767 and $<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zzI7FLRpTye2" title="Change in fair value of warrant liability">679,548 was included in other income (expense) for the three months ended March 31, 2026 and March 31, 2025, respectively. On November 17, 2023, concurrently with the closing of the Company’s registered direct offering, the Company issued warrants to purchase an aggregate of <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231115__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zOoNrMxuo4Mj" title="Warrants to purchase aggregate of common stock">169,697 shares of its Common Stock to the representative or its designees, at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231115__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zt0Y3GzjUuJ2" title="Warrants exercise price, per share">2.06 per share. These representative’s warrants were exercisable beginning <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_pid_c20231115__20231115__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zRY9OaynEGjf" title="Warrants exercisable date">November 15, 2023, and expire on November 15, 2028, pursuant to their terms and conditions. The representative’s warrants are not indexed to the Company’s own stock and therefore meet the definition of a derivative liability. The representative’s warrants are liability classified instruments and were initially recorded at a value of $123,811, which was determined using the Black-Scholes-Merton method using a term of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231115__20231115__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zua2F1kqeloe" title="Fair value assumptions, contractual term">4.88 years, risk free interest rate of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20231115__20231115__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_z8HE5vwL0RZi" title="Risk free interest rate">3.84% and volatility of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20231115__20231115__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_zCA4IgpixJk8" title="Volatility rate">90.0%. As of March 31, 2026 and December 31, 2025, the Company remeasured the warrant liability resulting in a value of $109,239 and $130,553 respectively. The gain on remeasurement of the warrant liability in the amount of $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_z75IhgBBaSej" title="Change in fair value of warrant liability">21,314 and $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--SubsidiarySaleOfStockAxis__custom--RegisteredDirectOfferingMember_z8iqvOALretd" title="Change in fair value of warrant liability">65,546 was included in other income (expense) for the three months ended March 31, 2026 and March 31, 2025, respectively. Concurrently with the closing of the Company’s private placement offering on March 28, 2024, the Company issued warrants to purchase an aggregate of up to <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240328__20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zbpWgHCpJOZc" title="Number of common stock sold">578,643 shares of its Common Stock to the investors in the private placement at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zADIIAg0nthg" title="Warrants exercise price, per share">2.55 per share. The warrants are exercisable beginning on <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_pid_c20240328__20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z5iksZpSwdI5" title="Warrants and rights exercisable period">September 28, 2024, and expire on September 28, 2029. The warrants were not indexed to the Company’s own stock and therefore meet the definition of a derivative liability. The warrants were liability classified instruments when issued and were initially recorded at a value of $1,190,111, which was determined using the Black-Scholes-Merton method using a term of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240328__20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zb1g25LeiB0j" title="Fair value assumptions, contractual term">5.5 years, risk free interest rate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240328__20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zMCufyBs8fk4" title="Risk free interest rate">4.20% and volatility of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240328__20240328__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z9yEif4SEGs2" title="Volatility rate">95.0 In May 2024, the Company amended the warrant agreements related to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240531__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zCzFj0a9Ov6d" title="Warrants to purchase aggregate of common stock">437,031 warrants to adjust them to be indexed to the Company’s own stock, and they were therefore reclassed to equity classified instruments in a non-cash transaction. When the warrants agreements were amended, the Company remeasured the warrant liability resulting in a final warrant value of $<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstanding_iI_c20240531__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--AmendmentOfWarrantAgreementsMember_zhRwcRFytH2g" title="Warrants">1,011,562. The warrant liability for these <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240531__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zviWDyjBOzMe" title="Warrants to purchase aggregate of common stock">437,031 warrants was removed and equity was increased by $<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstanding_iI_c20240531__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--AmendmentOfWarrantAgreementsMember_zTOl6HdYHnAj" title="Warrants">1,011,562 to account for the equity classification. The remaining <span id="xdx_90A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20260331__us-gaap--PlanNameAxis__custom--AmendmentOfWarrantAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ztk1XRhYk3tb" title="Warrant liability classified instruments">141,612 warrants remain liability classified instruments. As of March 31, 2026 and December 31, 2025, the Company remeasured the warrant liability, resulting in a value of $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_c20260331__us-gaap--PlanNameAxis__custom--AmendmentOfWarrantAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zcs8Kv1hdEdk" title="Warrants">98,870 and $<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstanding_iI_c20251231__us-gaap--PlanNameAxis__custom--AmendmentOfWarrantAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z79Ocj9epPUd" title="Warrants">117,613, respectively. The gain on remeasurement of the warrant liability in the amount of $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20260101__20260331__us-gaap--PlanNameAxis__custom--AmendmentOfWarrantAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ztyq4bMojymf" title="Change in fair value of warrant liability">18,743 and $<span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_c20250101__20250331__us-gaap--PlanNameAxis__custom--AmendmentOfWarrantAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zJKP5DxTRM35" title="Change in fair value of warrant liability">54,627 was included in other income (expense) for the three months ended March 31, 2026 and March 31, 2025, respectively. Concurrently with the closing of the Company’s private placement offering on February 24, 2025, the Company issued warrants to purchase an aggregate of up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zXUDM7iRZsFi" title="Number of common stock sold">1,810,000 shares of its Common Stock to the investors in the private placement at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zcxFgYTaHii2" title="Warrants exercise price, per share">1.87 per share. The warrants are exercisable beginning on <span id="xdx_900_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_pid_c20240224__20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zQW6lrfbIEIf" title="Warrants and rights exercisable period">February 24, 2026, and expire on <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_c20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z64yR6JWxPG1" title="Warrants and rights expiration date">February 24, 2031. The warrants issued were divided into two groups: warrants issued to directors and warrants issued to affiliated and non-affiliated investors. The warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember_zDRU1e6Ir6ek" title="Number of common stock sold">123,333 shares of the Company’s Common Stock issued to directors were deemed options issued under the MAIA 2021 Plan (as defined below) and are equity classified instruments and the value of these warrants determined using the Black-Scholes-Merton method was $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zNebgWViBQ96" title="Warrants">176,680 using a term of <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250224__20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_ziduv68oZqF5" title="Fair value assumptions, contractual term">6 years, risk free interest rate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250224__20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zDR9YUKyLEJi" title="Risk free interest rate">4.23% and volatility of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250224__20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zYYxYEJlb7fe" title="Volatility rate">95%. The warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--AffiliatedAndNonaffiliatedInvestorMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember_z9iqVkNyU5m7" title="Number of common stock sold">1,686,667 shares of the Company’s Common Stock issued to affiliated and non-affiliated investors are indexed to the Company’s own stock and they were therefore equity classified instruments and the value of these warrants determined using the Black-Scholes-Merton method was $<span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_c20250224__20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--AffiliatedAndNonaffiliatedInvestorMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zFaSbOH4k0pc" title="Change in fair value of warrant liability">2,416,223 using a term of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250224__20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--AffiliatedAndNonaffiliatedInvestorMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zRm9dDeXwtFi" title="Fair value assumptions, contractual term">6 years, risk free interest rate of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250224__20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--AffiliatedAndNonaffiliatedInvestorMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zwfpRzwMrLL2" title="Risk free interest rate">4.23% and volatility of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250224__20250224__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--AffiliatedAndNonaffiliatedInvestorMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zSMrzPMRW6i8" title="Volatility rate">95%. The total fair value ascribed to the warrants combined with the fair value of the common stock issued in the private placement was then used for purposes of allocation of the equity classified warrant value within the condensed consolidated statements of changes in the stockholders’ equity. Concurrently with the closing of the Company’s private placement offering on March 3, 2025, the Company issued warrants to purchase an aggregate of up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zM8Idc2X39z9" title="Number of common stock sold">952,633 shares of its Common Stock to the investors in the private placement at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zkRLUDIL7fV6" title="Warrants exercise price, per share">1.85 per share. The warrants are exercisable beginning on <span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_pid_c20250303__20250303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zqq7ln9Zij67" title="Warrants and rights exercisable period">March 3, 2026, and expire on March 3, 2031. The warrants issued were divided into two groups: warrants issued to directors and warrants issued to non-affiliated investors. The warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zhp7xQWkDYIk" title="Number of common stock sold">58,333 shares of the Company’s Common Stock issued to directors were deemed options issued under the MAIA 2021 Plan (as defined below) and are equity classified instruments and the value of these warrants determined using the Black-Scholes-Merton method was $<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstanding_iI_c20250303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zb4UEvKPkMaa" title="Warrants value">80,894 using a term of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250303__20250303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zzUwfNQWFiKi" title="Fair value assumptions, contractual term">6 years, risk free interest rate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250303__20250303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zLwHrMjgSU7g" title="Risk free interest rate">3.97% and volatility of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250303__20250303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_z9RbASQgX8Yk" title="Volatility rate">95%. The warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--NonaffiliatedInvestorsMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember_z25TLKQgbFDe" title="Warrants issued to purchase common stock">894,300 shares of the Company’s Common Stock issued to non-affiliated investors are indexed to the Company’s own stock and they were therefore equity classified instruments and the value of these warrants determined using the Black-Scholes-Merton method was $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20250303__20250303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--NonaffiliatedInvestorsMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_z0GNvMzsAn4" title="Change in fair value of warrant liability">1,240,185 using a term of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250303__20250303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zYlDze9gwkqd" title="Fair value assumptions, contractual term">6 years, risk free interest rate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250303__20250303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--NonaffiliatedInvestorsMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zvciaXCyBmoi" title="Risk free interest rate">3.97% and volatility of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250303__20250303__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--NonaffiliatedInvestorsMember__us-gaap--ValuationTechniqueAxis__custom--BlackSholesMethodMember_zPRUnLXVrY22" title="Volatility rate">95%. The total fair value ascribed to the warrants combined with the fair value of the common stock issued in the private placement was then used for purposes of allocation of the equity classified warrant value within the condensed consolidated statements of changes in the stockholders’ equity. SCHEDULE OF WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term in Years</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Balance at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20260101__20260331_zFGFaI89JnW" style="width: 12%; text-align: right" title="Warrants Outstanding, Beginning balance">13,086,220</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331_z8ss7oybH1vg" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning balance">1.92</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zEAIbzgNF4M3" title="Weighted Average Remaining Contractual Term in Years">3.13</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20260101__20260331_zTxXEE0MgS4e" style="text-align: right" title="Warrants Outstanding, Issued">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331_zoZc62D6vW96" style="text-align: right" title="Weighted Average Exercise Price, Issued">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260101__20260331_zuYCqxzb8yvf" style="text-align: right" title="Warrants Outstanding, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20260101__20260331_z1DIgkzZhsMc" style="text-align: right" title="Weighted Average Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20260101__20260331_zJ8MzB7l5bO9" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Outstanding, Expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice_c20260101__20260331_zaV8LYBp6LE1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20260101__20260331_zt1wYP5kyBub" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending balance">13,086,220</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331_zD34587MMhx7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending balance">1.92</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_zxZQ1ItIjjQ2" title="Weighted Average Remaining Contractual Term in Years">2.89</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term in Years</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Balance at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250331_zgMxTtbMwOMe" style="width: 12%; text-align: right" title="Warrants Outstanding, Beginning balance">6,718,176</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250331_zPvGoHk7DfBa" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning balance">2.37</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zhMY8baioSB4" title="Weighted Average Remaining Contractual Term in Years">4.56</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250331_zOkCYmQRXoFl" style="text-align: right" title="Warrants, Issued">2,580,967</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331_zecBzpU6JTdk" style="text-align: right" title="Weighted Average Exercise Price, Issued">3.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20250101__20250331_zAHUvpv1yoO3" style="text-align: right" title="Warrants, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20250331_zk1hjhtIyNF7" style="text-align: right" title="Weighted Average Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20250101__20250331_zwzpL79kbnf7" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, Expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250331_zXGJdR6zu3Dc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250331_zoxqu16YP8M8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending balance">9,299,143</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250331_znVJCKEL56Pa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending balance">2.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331_z8MtRZAecDSd" title="Weighted Average Remaining Contractual Term in Years">4.76</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_89F_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zAPZEcTI9N6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">The value of warrant grants is calculated using the Warrant Black Scholes calculations with the following assumptions for warrants granted during the three months ended March 31, 2026 and 2025: SCHEDULE OF SHARE-BASED PAYMENT AWARD, WARRANTS, VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zl1hpk4nQU04" title="Risk-free interest rate, minimum">—% -<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7OXqRIErys1" title="Risk-free interest rate, maximum"> —</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeGaLJ5PMTTl" title="Risk-free interest rate, minimum">3.97% - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8sYrxIbou6l" title="Risk-free interest rate, maximum">4.23</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Expected term (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJKS6DSh2mA6" title="Fair value assumptions, contractual term">0.0</td><td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zw3rvadElvA8" title="Fair value assumptions, contractual term">6.0</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaJ7OMoQt7O6" title="Volatility rate">—</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrMdqqvtaPaf" title="Volatility rate">95</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQ5PSKd34TJ4" title="Expected dividend yield">—</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8JfDJaEkbhk" title="Expected dividend yield">—</td><td style="text-align: left"> </td> </tr> </table> MAIA Biotechnology, Inc. Stock Option and Equity Incentive Plans In 2018, the Company adopted the MAIA Biotechnology, Inc. 2018 Stock Option Plan (the “MAIA 2018 Plan”). MAIAs board of directors administers the MAIA 2018 Plan for the purposes of attracting, retaining, and motivating key employees, directors, and consultants of MAIA. The terms of the MAIA 2018 Plan continue to govern the <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandEighteenStockOptionPlanMember_zlEUEYybcXnl" title="Stock options outstanding">1,752,945 options outstanding under the plan as of March 31, 2026. In 2020, the Company adopted the MAIA Biotechnology, Inc. Amended and Restated 2020 Equity Incentive Plan (the “MAIA 2020 Plan”), also administered by the board of directors. The MAIA 2020 Plan permitted awards to take the form of stock options, restricted stock and restricted stock units. The terms of the MAIA 2020 Plan continue to govern the <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260331__us-gaap--PlanNameAxis__custom--AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_zuHVabgViPD2" title="Stock options outstanding">3,503,589 options outstanding in the plan as of March 31, 2026. There are no shares reserved for future issuance under the MAIA 2018 Plan or the MAIA 2020 Plan. On August 1, 2022 the Company approved the MAIA Biotechnology,Inc.’s 2021 Equity Incentive Plan (“the MAIA 2021 Plan”) with <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220801__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember_zpSwlYvKkqjj" title="Common stock reserved for issuance">1,909,518 shares of Common Stock reserved for issuance. On May 25, 2023 the MAIA 2021 Plan was amended to include an automatic increase to the plan in the amount equal to <span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfIncreaseInStockOutstandingFullyDiluted_pid_dp_uPure_c20230525__20230525__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember_z4ZJIWBzBRdj" title="Percentage of increase in stock outstanding fully diluted">10% of the total number of shares of stock outstanding on a fully diluted basis on December 31 of the preceding calendar year (the “Increase Date”); provided that, the board of directors may act prior to any Increase Date to provide that there will be no increase for such year or that the increase for such year will be a lesser number of shares of stock. The amount reserved for issuance under the MAIA 2021 Plan increased by <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember_zgLi7DsPyyQ8" title="Common stock reserved for issuance">1,956,993 based on the fully diluted shares outstanding as of December 31, 2022. The amount reserved for issuance under the MAIA 2021 Plan increased by <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240101__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember_zrvPf4awCSQj" title="Common stock reserved for issuance">2,838,668 shares on January 1, 2024 based on the fully diluted shares outstanding as of December 31, 2023. The amount reserved for issuance under the MAIA 2021 Plan increased by (i) <span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250101__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember_zTxjDowAWeq3" title="Common stock reserved for issuance">2,250,000 shares on January 1, 2025 based on the fully diluted shares outstanding as of December 31, 2024 (and the discretion of the Company’s board of directors to authorize less than 10% of such amount) and (ii) <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20260101__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember_zQ42nfwQTr9g" title="Common stock reserved for issuance">6,458,889 shares on January 1, 2026, based on the fully diluted shares outstanding as of December 31, 2025. As of March 31, 2026, there are <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember_zcoyjAsw2tJ3" title="Common stock reserved for issuance">6,648,953 shares of Common Stock available for future issuance under the MAIA 2021 Plan and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember_z1AU5odnzMC2" title="Stock options outstanding">7,841,457 options are outstanding under the MAIA 2021 Plan. Stock options are to be granted with an exercise price which is at least equal to the stock’s estimated fair value at the date of grant, and with a contractual term of no more than <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20260101__20260331__srt--RangeAxis__srt--MaximumMember_z8NscFrh1OGi" title="Options contractual term">ten years from the date of grant. In the case of an option granted to a <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted_pid_dp_uPure_c20260101__20260331_zvzQEkWM64Vk" title="Percentage of shares granted">10% stockholder, the exercise price shall be generally no less than <span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage_pid_dp_uPure_c20260101__20260331_zRPgTJsTXwG" title="Exercise price percentage">110% of the fair market value per share on the date of grant, and the contractual term shall be seven years. Outstanding options awarded under the MAIA 2021 Plan may, but need not, vest and therefore become exercisable in periodic installments that may, but need not, be equal. The option may be subject to other terms and conditions as to the time or times when it may be exercised (which may be based on performance or other criteria) as the board of directors may deem appropriate. Unexercised options are cancelled ninety days after termination of an employee, director, founder, or consultant. Unexercised options are cancelled immediately if an employee, director, founder, or consultant is terminated for cause; under certain other circumstances, the period to cancellation may differ as described in the respective plan documents. Certain clauses in the Plans also govern the Company’s exercise repurchase rights and various other features of awards granted under the plans. As of March 31, 2026, only stock options have been awarded pursuant to the MAIA stock option and equity incentive plans. The following table summarizes the activity and information regarding MAIA’s outstanding and exercisable options for the three months ended March 31, 2026: SCHEDULE OF ACTIVITY AND INFORMATION OF OUTSTANDING AND EXERCISABLE OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term in Years</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Balance at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260101__20260331_zxATbBN2BEDj" style="width: 12%; text-align: right" title="Options Outstanding, Beginning balance">12,878,381</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260331_zfdkrH5cOrH8" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning balance">2.19</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zcFkeZC2KfM5" title="Weighted Average Remaining Contractual Term in Years">6.68</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260331_z2A77GW3e28l" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value, Beginning balance">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260331_zkjgimePD7yj" style="text-align: right" title="Options, Granted">641,089</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260331_zptrzjV2khC4" style="text-align: right" title="Weighted Average Exercise Price, Granted">1.49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20260101__20260331_zPc2AyAeB7N1" style="text-align: right" title="Options, Exercised">(21,479</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20260101__20260331_z1ZFLlVve8Yg" style="text-align: right" title="Weighted Average Exercise Price, Exercised">1.79</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cancelled/forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20260101__20260331_zllT6g9nT5Q3" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Cancelled/forfeited">(400,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260331_zgbRNZN1Qp6j" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled/forfeited">1.44</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260101__20260331_zJJpgjkTenp9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Ending balance">13,097,991</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260331_zFd4EU5PSvT4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending balance">2.17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_z4OfclxpsuQ6" title="Weighted Average Remaining Contractual Term in Years, Outstanding">6.26</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331_zMuxydtAp0Pf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Ending balance">122,238</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Options exercisable at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260331_znTTLYj3CEf" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Exercisable">10,263,053</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260331_zociwY24UBVc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable">2.24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331_zGDEubocQ3ya" title="Weighted Average Remaining Contractual Term in Years, Exercisable">5.7</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331_zaNVJhiJkzr1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable">112,947</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zpfqXz2KIkB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">The value of option grants is calculated using the Black-Scholes-Merton option pricing model with the following assumptions for options granted during the three months ended March 31, 2026 and 2025: SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5VOTR4T5D1b" title="Risk-free interest rate, minimum">3.52% - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlBjoRrfXgI1" title="Risk-free interest rate, maximum">3.70 </td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zw1Xu2rOm0Bi" title="Risk-free interest rate, minimum">4.22% - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zB4O2wMzSxWl" title="Risk-free interest rate, maximum">4.43 </td><td style="text-align: left">%</td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYx1lVUGpxEc" title="Fair value assumptions, contractual term">5 – <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znKA28nBseJ5" title="Fair value assumptions, contractual term">5.3</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBcA0LC74ZHa" title="Fair value assumptions, contractual term">5 - <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5jPn2bNoZL3" title="Fair value assumptions, contractual term">6.08</td><td style="text-align: left"> </td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 53%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 19%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zR5Vu4lagPRa" title="Volatility rate">85</td><td style="width: 1%; text-align: left">%</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 19%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhfLbDsNnwBc" title="Volatility rate">95</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNPQctMklaXd" title="Expected dividend yield">—</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNH6sTg08a6" title="Expected dividend yield">—</td><td style="text-align: left">%</td><td> </td> </tr> </table> The weighted-average grant date fair value of stock options issued during the three months ended March 31, 2026 and 2025 was $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zy4Ksr7Z4iv7" title="Weighted-average grant date fair value">1.49 and $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziGNd7LWVzH7" title="Weighted-average grant date fair value">1.85, respectively. As of March 31, 2026, the total unrecognized compensation related to unvested employee and non-employee stock option awards granted was $<span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zb6UJh1U5Xh1" title="Unrecognized compensation">3,105,891, which the Company expects to recognize over a weighted average period of approximately <span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztMqFolJhQc2" title="Unrecognized compensation expense, recognized period">2.17 years. During the three months ended March 31, 2026, the Company granted performance-based stock options to a strategic advisor (the “Consultant”) under the MAIA 2021 Plan. The grant consists of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zxr2W5HCq6w1" title="Options granted">400,000 stock options, which represent the right to purchase shares of the Company’s common stock at $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zO3qo108QEIa" title="Weighted average exercise price">1.49 upon the achievement of specific performance milestones. The stock options are divided into two tranches, each subject to the following performance conditions: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Tranche 1: <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zHrn02827Jwe" title="Options granted">100,000 stock options will be vested upon completion of a new or modification of an existing supply and non-exclusive license agreement.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Tranche 2: <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zBLJ6ZXm8V1g" title="Options granted">300,000 stock options will be vested upon the completion of any contractual agreement in which a third party gains license rights to the Company’s patents or intellectual property or will be vested upon the completion of a transaction in which the Company raises more than $<span id="xdx_909_eus-gaap--Investments_iI_pn6n6_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zTjOx1bqAdY1" title="Investment amount">10 million form an investor or group of investors in exchange for a royalty or equity representing more than <span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfIncreaseInStockOutstandingFullyDiluted_pid_dp_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneEquityIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zKpN08584yTc">5% of the Company’s fully diluted shares outstanding.</td></tr></table> The Company estimates the fair value of these awards on the date of grant. For the performance-based milestones, expense is recognized over the requisite service period only when it is deemed probable that the performance conditions will be met. As of March 31, 2026, the Company determined that the achievement of Tranche 1 and Tranche 2 milestones were not probable. Consequently, the Company did not recognize any stock-based compensation expense within General and Administrative expenses for the period. <p id="xdx_89D_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zn4jTEr18uYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">Stock based compensation related to the Company’s stock plans are as follows: SCHEDULE OF STOCK BASED COMPENSATION EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260101__20260331_zcppt2nh9PP8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250101__20250331_zOZeVI0E4a77" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_ecustom--AllocatedShareBasedCompensationExpenseGeneralAndAdministrative_maASBCEz9sn_zcd8GQGd2m3l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">General and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">440,736</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">198,858</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--AllocatedShareBasedCompensationExpenseResearchAndDevelopment_maASBCEz9sn_z5MMagSLmaT7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">209,288</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">172,614</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_iT_mtASBCEz9sn_zk4m0qM2WPWg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">650,024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">371,472</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

70000000

30000000

70000000

150000000

30000000

0.0001

1445000 4950000 30000000 11200000

666323

2.28

1521091

45633

84587

1390871

1810000

1.50

2700000

1.87

P6Y

2031-02-24

952633

1.50

1400000

1.85

P6Y

2031-03-03

20000000

1.50

30000000

1500000

329000

28171000

2005875

1.50

3009000

150000

16000

2843000

43651

19848

100000

6.25

2023-01-23

2027-07-27

15000

343735

P5Y

0.0282

0.775

4324

27455

23131

26268

2424243

1.86

1903915

P5Y4M17D

0.0385

0.900

909091

458726

2815970

1025007

1216774

191767

679548

169697

2.06

2023-11-15

2028-11-15

123811

P4Y10M17D

0.0384

0.900

109239

130553

21314

65546

578643

2.55

2024-09-28

2029-09-28

1190111

P5Y6M

0.0420

0.950

437031

1011562

437031

1011562

141612

98870

117613

18743

54627

1810000

1.87

2026-02-24

2031-02-24

123333

176680

P6Y

0.0423

0.95

1686667

2416223

P6Y

0.0423

0.95

952633

1.85

2026-03-03

2031-03-03

58333

80894

P6Y

0.0397

0.95

894300

1240185

P6Y

0.0397

0.95

SCHEDULE OF WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term in Years</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Balance at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20260101__20260331_zFGFaI89JnW" style="width: 12%; text-align: right" title="Warrants Outstanding, Beginning balance">13,086,220</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331_z8ss7oybH1vg" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning balance">1.92</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zEAIbzgNF4M3" title="Weighted Average Remaining Contractual Term in Years">3.13</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20260101__20260331_zTxXEE0MgS4e" style="text-align: right" title="Warrants Outstanding, Issued">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331_zoZc62D6vW96" style="text-align: right" title="Weighted Average Exercise Price, Issued">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20260101__20260331_zuYCqxzb8yvf" style="text-align: right" title="Warrants Outstanding, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20260101__20260331_z1DIgkzZhsMc" style="text-align: right" title="Weighted Average Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20260101__20260331_zJ8MzB7l5bO9" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Outstanding, Expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice_c20260101__20260331_zaV8LYBp6LE1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20260101__20260331_zt1wYP5kyBub" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending balance">13,086,220</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331_zD34587MMhx7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending balance">1.92</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_zxZQ1ItIjjQ2" title="Weighted Average Remaining Contractual Term in Years">2.89</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term in Years</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Balance at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250331_zgMxTtbMwOMe" style="width: 12%; text-align: right" title="Warrants Outstanding, Beginning balance">6,718,176</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250331_zPvGoHk7DfBa" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning balance">2.37</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zhMY8baioSB4" title="Weighted Average Remaining Contractual Term in Years">4.56</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250331_zOkCYmQRXoFl" style="text-align: right" title="Warrants, Issued">2,580,967</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20250331_zecBzpU6JTdk" style="text-align: right" title="Weighted Average Exercise Price, Issued">3.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20250101__20250331_zAHUvpv1yoO3" style="text-align: right" title="Warrants, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20250331_zk1hjhtIyNF7" style="text-align: right" title="Weighted Average Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20250101__20250331_zwzpL79kbnf7" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants, Expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250331_zXGJdR6zu3Dc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250331_zoxqu16YP8M8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Ending balance">9,299,143</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250331_znVJCKEL56Pa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending balance">2.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250331_z8MtRZAecDSd" title="Weighted Average Remaining Contractual Term in Years">4.76</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

13086220

1.92 P3Y1M17D

13086220

1.92 P2Y10M20D

6718176

2.37 P4Y6M21D

2580967

3.01

9299143

2.23 P4Y9M3D <p id="xdx_89F_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zAPZEcTI9N6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">The value of warrant grants is calculated using the Warrant Black Scholes calculations with the following assumptions for warrants granted during the three months ended March 31, 2026 and 2025: SCHEDULE OF SHARE-BASED PAYMENT AWARD, WARRANTS, VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zl1hpk4nQU04" title="Risk-free interest rate, minimum">—% -<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7OXqRIErys1" title="Risk-free interest rate, maximum"> —</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeGaLJ5PMTTl" title="Risk-free interest rate, minimum">3.97% - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8sYrxIbou6l" title="Risk-free interest rate, maximum">4.23</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Expected term (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJKS6DSh2mA6" title="Fair value assumptions, contractual term">0.0</td><td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zw3rvadElvA8" title="Fair value assumptions, contractual term">6.0</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaJ7OMoQt7O6" title="Volatility rate">—</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrMdqqvtaPaf" title="Volatility rate">95</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQ5PSKd34TJ4" title="Expected dividend yield">—</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8JfDJaEkbhk" title="Expected dividend yield">—</td><td style="text-align: left"> </td> </tr> </table>

0.0397

0.0423

P0Y

P6Y

0.95

1752945

3503589

1909518

0.10

1956993

2838668

2250000

6458889

6648953

7841457

P10Y

0.10 1.10

P7Y

The following table summarizes the activity and information regarding MAIA’s outstanding and exercisable options for the three months ended March 31, 2026: SCHEDULE OF ACTIVITY AND INFORMATION OF OUTSTANDING AND EXERCISABLE OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term in Years</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Balance at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260101__20260331_zxATbBN2BEDj" style="width: 12%; text-align: right" title="Options Outstanding, Beginning balance">12,878,381</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260331_zfdkrH5cOrH8" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning balance">2.19</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zcFkeZC2KfM5" title="Weighted Average Remaining Contractual Term in Years">6.68</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260331_z2A77GW3e28l" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value, Beginning balance">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260331_zkjgimePD7yj" style="text-align: right" title="Options, Granted">641,089</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260331_zptrzjV2khC4" style="text-align: right" title="Weighted Average Exercise Price, Granted">1.49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20260101__20260331_zPc2AyAeB7N1" style="text-align: right" title="Options, Exercised">(21,479</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20260101__20260331_z1ZFLlVve8Yg" style="text-align: right" title="Weighted Average Exercise Price, Exercised">1.79</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cancelled/forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20260101__20260331_zllT6g9nT5Q3" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Cancelled/forfeited">(400,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260331_zgbRNZN1Qp6j" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled/forfeited">1.44</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260101__20260331_zJJpgjkTenp9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Ending balance">13,097,991</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260331_zFd4EU5PSvT4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending balance">2.17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_z4OfclxpsuQ6" title="Weighted Average Remaining Contractual Term in Years, Outstanding">6.26</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331_zMuxydtAp0Pf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Ending balance">122,238</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Options exercisable at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260331_znTTLYj3CEf" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Exercisable">10,263,053</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260331_zociwY24UBVc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable">2.24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331_zGDEubocQ3ya" title="Weighted Average Remaining Contractual Term in Years, Exercisable">5.7</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331_zaNVJhiJkzr1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable">112,947</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

12878381

2.19

P6Y8M4D

641089

1.49

21479

1.79

400000

1.44

13097991

2.17

P6Y3M3D

122238

10263053

2.24

P5Y8M12D

112947

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zpfqXz2KIkB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">The value of option grants is calculated using the Black-Scholes-Merton option pricing model with the following assumptions for options granted during the three months ended March 31, 2026 and 2025: SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5VOTR4T5D1b" title="Risk-free interest rate, minimum">3.52% - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlBjoRrfXgI1" title="Risk-free interest rate, maximum">3.70 </td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zw1Xu2rOm0Bi" title="Risk-free interest rate, minimum">4.22% - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zB4O2wMzSxWl" title="Risk-free interest rate, maximum">4.43 </td><td style="text-align: left">%</td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYx1lVUGpxEc" title="Fair value assumptions, contractual term">5 – <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znKA28nBseJ5" title="Fair value assumptions, contractual term">5.3</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBcA0LC74ZHa" title="Fair value assumptions, contractual term">5 - <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5jPn2bNoZL3" title="Fair value assumptions, contractual term">6.08</td><td style="text-align: left"> </td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 53%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 19%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zR5Vu4lagPRa" title="Volatility rate">85</td><td style="width: 1%; text-align: left">%</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 19%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhfLbDsNnwBc" title="Volatility rate">95</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNPQctMklaXd" title="Expected dividend yield">—</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNH6sTg08a6" title="Expected dividend yield">—</td><td style="text-align: left">%</td><td> </td> </tr> </table>

0.0352

0.0370

0.0422

0.0443

P5Y

P5Y3M18D

P5Y

P6Y29D

0.85

0.95

1.49

1.85

3105891

P2Y2M1D

400000

1.49

100000

300000

10000000

0.05

<p id="xdx_89D_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zn4jTEr18uYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify">Stock based compensation related to the Company’s stock plans are as follows: SCHEDULE OF STOCK BASED COMPENSATION EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260101__20260331_zcppt2nh9PP8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250101__20250331_zOZeVI0E4a77" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_ecustom--AllocatedShareBasedCompensationExpenseGeneralAndAdministrative_maASBCEz9sn_zcd8GQGd2m3l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">General and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">440,736</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">198,858</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--AllocatedShareBasedCompensationExpenseResearchAndDevelopment_maASBCEz9sn_z5MMagSLmaT7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">209,288</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">172,614</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_iT_mtASBCEz9sn_zk4m0qM2WPWg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">650,024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">371,472</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

440736 198858 209288 172614

650024

371472

6. COMMITMENTS AND CONTINGENCIES Legal From time to time, the Company is involved in legal actions and claims arising in the normal course of business. Management believes there are no matters which will have a material adverse effect on the Company’s financial position, operations or cash flows. Patent Licensing, Sponsored Research, and Patent & Technology Agreements Ateganosine (THIO) In November 2018 and as amended in December 2020, the Company entered into a Global Patent Licensing Agreement (“PLA”) titled “Patent and Technology License Agreement AGT. NO. L2264 – MAIA Biotechnology” with the University of Texas Southwestern (“UTSW”) to license patent families for a specific compound (“THIO”) from UTSW to MAIA (the “UTSW Agreement”). The UTSW Agreement, as amended, has a term of <span id="xdx_907_ecustom--TermOfAgreement_dtY_c20181101__20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AteganosineTHIOTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--AmendedPatentAndTechnologyLicenseAgreementMember_zhTV7V06b7md" title="Term of agreement">20 years. The agreement requires MAIA to reimburse UTSW for agreed-upon expenses related to THIO. The UTSW Agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $<span id="xdx_900_ecustom--MilestonePayment_c20181101__20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AteganosineTHIOTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--AmendedPatentAndTechnologyLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zuLBicEIFsDh" title="Milestone payment">1,000,000 and $<span id="xdx_90D_ecustom--MilestonePayment_c20181101__20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AteganosineTHIOTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--AmendedPatentAndTechnologyLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zmgGXSSLmPU8" title="Milestone payment">50,000,000, not to exceed a combined milestone payment total of $<span id="xdx_90C_ecustom--CombinedMilestonePaymentsMaximum_c20181101__20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AteganosineTHIOTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--AmendedPatentAndTechnologyLicenseAgreementMember_zGq0Go2zab6h" title="Combined milestone payment maximum">112,000,000. As of March 31, 2026, no assignment has occurred and none of the defined milestones have been completed and therefore <span id="xdx_909_ecustom--PaymentsDueRelatedToMilestones_do_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfTexasSouthwesternMember__us-gaap--TypeOfArrangementAxis__custom--AmendedPatentAndTechnologyLicenseAgreementMember_zWRF6193VC95" title="Payments due related to milestones">no payments are due to UTSW related to the milestones. The UTSW Agreement requires MAIA to make royalty payments of: (i) <span id="xdx_903_ecustom--PercentageOfRoyaltyPaymentsOnNetSales_pid_dp_uPure_c20181101__20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AteganosineTHIOTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--AmendedPatentAndTechnologyLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetSalesUptoOneBillionMember_zGUQUHp2QKd8" title="Rate of royalties on net sales">2-<span id="xdx_907_ecustom--PercentageOfRoyaltyPaymentsOnNetSales_pid_dp_uPure_c20181101__20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AteganosineTHIOTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--AmendedPatentAndTechnologyLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetSalesUptoOneBillionMember_z8T3REKk2Nbj" title="Rate of royalties on net sales">4% (depending on THIO reaching specified sales levels in the respective jurisdictions) on net sales up to $1,000,000,000; and (ii) <span id="xdx_908_ecustom--PercentageOfRoyaltyPaymentsOnNetSales_pid_dp_uPure_c20181101__20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AteganosineTHIOTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--AmendedPatentAndTechnologyLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetSalesAboveOneBillionMember_z5t3cSqc8CA4" title="Rate of royalties on net sales">2.5-<span id="xdx_904_ecustom--PercentageOfRoyaltyPaymentsOnNetSales_pid_dp_uPure_c20181101__20181130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AteganosineTHIOTherapeuticsIncMember__us-gaap--TypeOfArrangementAxis__custom--AmendedPatentAndTechnologyLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetSalesAboveOneBillionMember_zg5VVVoxwDc2" title="Rate of royalties on net sales">5% on net sales above $1,000,000,000. Also in December 2020, the Company entered into a second license agreement with UTSW titled “Patent and Technology License Agreement AGT. NO. L3648 — MAIA Biotechnology” pursuant to which UTSW is licensing an additional compound to MAIA (the “UTSW2 Agreement”). The UTSW2 Agreement has a term of <span id="xdx_903_ecustom--TermOfAgreement_dtY_c20201201__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfTexasSouthwesternMember__us-gaap--TypeOfArrangementAxis__custom--PatentAndTechnologyLicenseAgreementMember_zsdlVKAA1gT8" title="Term of agreement">20 years and requires the Company to reimburse UTSW for certain agreed-upon expenses. The UTSW2 Agreement requires certain payments upon assignment of the license to a third party as well as upon reaching specific milestones, ranging between $<span id="xdx_904_ecustom--MilestonePayment_c20201201__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfTexasSouthwesternMember__us-gaap--TypeOfArrangementAxis__custom--PatentAndTechnologyLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zxtNVkuRhH1e" title="Milestone payment">1,000,000 and $<span id="xdx_909_ecustom--MilestonePayment_c20201201__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfTexasSouthwesternMember__us-gaap--TypeOfArrangementAxis__custom--PatentAndTechnologyLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zKV8el4EW2nh" title="Milestone payment">50,000,000, not to exceed a combined milestone payment total of $<span id="xdx_900_ecustom--CombinedMilestonePaymentsMaximum_c20201201__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfTexasSouthwesternMember__us-gaap--TypeOfArrangementAxis__custom--PatentAndTechnologyLicenseAgreementMember_zWhslnxPq0Ci" title="Combined milestone payment maximum">112,000,000. As of March 31, 2026, no assignment has occurred and none of the defined milestones have been completed and therefore <span id="xdx_90A_ecustom--PaymentsDueRelatedToMilestones_do_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfTexasSouthwesternMember__us-gaap--TypeOfArrangementAxis__custom--AmendedPatentAndTechnologyLicenseAgreementMember_zF5ubT26wWp4" title="Payments due related to milestones">no payments are due to UTSW related to the milestones. The UTSW2 Agreement requires MAIA to make royalty payments of: (i) <span id="xdx_901_ecustom--PercentageOfRoyaltyPaymentsOnNetSales_pid_dp_uPure_c20201201__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfTexasSouthwesternMember__us-gaap--TypeOfArrangementAxis__custom--PatentAndTechnologyLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetSalesUptoOneBillionMember_zyS44wtWzxd6" title="Rate of royalties on net sales">2-<span id="xdx_90E_ecustom--PercentageOfRoyaltyPaymentsOnNetSales_pid_dp_uPure_c20201201__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfTexasSouthwesternMember__us-gaap--TypeOfArrangementAxis__custom--PatentAndTechnologyLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetSalesUptoOneBillionMember_zCWciqgzFe97" title="Rate of royalties on net sales">4% (depending on THIO reaching specified sales levels in the respective jurisdictions) on net sales up to $1,000,000,000; (ii) and <span id="xdx_90A_ecustom--PercentageOfRoyaltyPaymentsOnNetSales_pid_dp_uPure_c20201201__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfTexasSouthwesternMember__us-gaap--TypeOfArrangementAxis__custom--PatentAndTechnologyLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetSalesAboveOneBillionMember_zdUymEqHt2Tg" title="Rate of royalties on net sales">2.5-<span id="xdx_905_ecustom--PercentageOfRoyaltyPaymentsOnNetSales_pid_dp_uPure_c20201201__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfTexasSouthwesternMember__us-gaap--TypeOfArrangementAxis__custom--PatentAndTechnologyLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--NetSalesAboveOneBillionMember_zUt9uugUXfR8" title="Rate of royalties on net sales">5% on net sales above $1,000,000,000. The Company will also pay UTSW running royalties on a yearly basis as a percentage of Net Sales (as defined in the UTSW2 Agreement) of the Company or its sublicensee. <span id="xdx_90D_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesDescription_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityOfTexasSouthwesternMember__us-gaap--TypeOfArrangementAxis__custom--PatentAndTechnologyLicenseAgreementMember_z7hKGFJrUAOh" title="Percentage of royalty description">There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the UTSW2 Agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by 50%. The royalty obligations continue on a country-by-country basis until the later of expiration of the last Valid Claim in each country or 10 years after the First Commercial Sale (as defined in UTSW2 Agreement) in each country. Regeneron In February 2021, the Company entered into a Drug Supply Agreement (the “Drug Supply Agreement”) with Regeneron Pharmaceuticals, Inc. (“Regeneron”) to perform one clinical trial for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) involving a Regeneron drug candidate that utilizes one of the Company’s compounds/agents. The Company is responsible for all costs of the study with Regeneron supplying their drug cemiplimab representing a cost savings for the Company, the first phase of which is expected to take approximately two years. The overall term of the agreement is for five years unless earlier terminated for certain reasons as defined in the agreement. Either party may terminate a study plan in the event that patient screening for the clinical study does not commence within 12 months after: (i) the Effective Date (as defined in the Drug Supply Agreement), with respect to the initial study; or (ii) the execution of the applicable study plan, with respect to each other study. If either party terminates a study plan, the Company shall reimburse Regeneron for the Regeneron product it received in connection with such study plan based on the actual out-of-pocket cost to Regeneron of such Regeneron product. As of March 31, 2026, neither party has terminated the agreement. BeOne In December 2024, the Company reached an agreement with BeOne Medicines, Ltd., (“BeOne”) to perform certain clinical trials for the treatment of patients with small cell lung cancer (SCLC), liver cancer (HCC), and colorectal cancer (CRC) involving a BeOne drug candidate that utilizes one of the Company’s compounds/agents. The Company is responsible for all costs of the study with BeOne supplying their drug tislelizumab representing a cost savings for the Company. The overall term of the agreement is for seven years unless earlier terminated for certain reasons as defined in the agreement. As of March 31, 2026, neither party has terminated the agreement. Roche In June 2025, the Company reached an agreement with F. Hoffman-La Roche Ltd, (“Roche”) to perform certain clinical trials for the treatment of patients with hard-to-treat cancers involving Roche’s checkpoint inhibitor, atezolizumab (Tecentriq®). The Company is responsible for all costs of the study with Roche supplying their drug atezolizumab representing a cost savings for the Company. The overall term of the agreement is for five years unless earlier terminated for certain reasons as defined in the agreement. As of March 31, 2026, neither party has terminated the agreement.

P20Y 1000000 50000000 112000000 0 0.02 0.04 0.025 0.05 P20Y 1000000 50000000 112000000 0 0.02 0.04 0.025 0.05 There are single digit royalty rates for licensed products and licensed services covered by a Valid Claim (as defined in the UTSW2 Agreement) and dependent on whether Net Sales are greater than or less than/equal to $1,000,000,000, with Net Sales above that amount commanding a slightly higher percentage. In each case, the royalty percentage is lower before patent issuance in each jurisdiction. In the event that the licensed product or licensed service is not covered by a Valid Claim, the running royalty rates are reduced by 50%. P5Y P7Y

7. INCOME TAXES The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The issuance of shares in connection with the Company’s IPO, as well as prior share issuances, may result in limitations on the utilization of the Company’s net operating loss carryforwards under IRC section 382. As of March 31, 2026, and December 31, 2025, the Company had a full valuation allowance against its deferred tax assets. No provision or benefit for U.S. federal, state, or Australian income taxes has been recorded for the three months ended March 31, 2026 and 2025, mainly due to net losses incurred by the Company. A provision of $339 and zero for Romanian income tax was recorded for the three months ended March 31, 2026 and 2025.

339

8. SEGMENT INFORMATION The Company operates in one reportable segment. This determination is based on the Company’s structure, the manner in which the chief operating decision maker (“CODM”) reviews the operating results to assess performance and allocate resources, and the nature of the Company’s operations. Segment assets are reported as total assets on the consolidated balance sheet. The CODM, who is the Chief Executive Officer, regularly reviews consolidated financial information, such as consolidated net loss. The CODM’s review is for the purpose of assessing performance and making decisions about resource allocation. See our consolidated financial statements in Part I, “Item 1, Financial Statements”, and Note 1, “Description of Business, Organization, and Principles of Consolidation” for additional information about these line items and the related accounting policies.

The CODM, who is the Chief Executive Officer, regularly reviews consolidated financial information, such as consolidated net loss. The CODM’s review is for the purpose of assessing performance and making decisions about resource allocation.

9. GOVERNMENT GRANTS The Company receives research grants from the National Institutes of Health (NIH) to support specific primary research and clinical development projects. In accordance with ASU 2025-10, the Company accounts for these as government grants and has elected the income-related approach. Grant proceeds are recognized in the consolidated statements of operations when there is reasonable assurance that the Company will comply with the conditions attached to the grant and the grant will be received. The Company has elected to present these grant proceeds as a component of Other income, net, rather than as a reduction of the related Research and Development (R&D) expenses. During the quarter ended March 31, 2026, the Company operated under one active NIH Small Business Innovation Research (SBIR) awards (Award #1R44CA309843-01). These grants are cost-reimbursable, meaning the Company is entitled to payment only after incurring allowable costs as defined by the NIH Grants Policy Statement. As of March 31, 2026, the Company has recognized a receivable of approximately $0.2 million for qualified R&D expenditures that have been incurred but not yet reimbursed by the NIH. NIH grants are subject to audit and retrospective adjustment by the granting agency to ensure compliance. While the Company believes it has complied with all material terms of the grant agreements, any costs found to be unallowable upon audit could be subject to repayment. As of March 31, 2026, no such repayment is deemed probable.

200000

10. SUBSEQUENT EVENTS Issuance of Options From April 1 to May 11, 2026, the Company issued <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20260401__20260511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantsMember_z7T3NzUqDf24" title="Number of option issued">1,488,082 options at a weighted exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260401__20260511__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantsMember_zvgRo6QSQ6Tb" title="Weighted exercise price">1.28 to employees and consultants. Issuance of Stock On April 10, 2026, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20260410__20260410__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember_zFfuWotYSCv1" title="Issuance of shares">7,951 restricted shares of Common Stock having a value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20260410__20260410__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember_z343lheSr4cb" title="Issuance of shares, value">14,550 (based on the $<span id="xdx_900_eus-gaap--SharePrice_iI_c20260410__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember_zisXYVhu28Hh" title="Share price">1.83 price calculated by using 120% of the dollar value weighted average price of our common stock on the New York Stock Exchange for the thirty (30) trading days immediately preceding the date of the purchase payment) to a service provide under a master services agreement in consideration of services rendered. The issuance was exempt under Section 4(a)(2) of the securities Act of 1933, as amended. On April 10, 2026, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20260410__20260410__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FGMKBusinessHoldingsLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOfAEQn5ysN3" title="Number of common stock sold">15,492 restricted shares of Common Stock having a value of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20260410__20260410__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FGMKBusinessHoldingsLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLz0SC41A4s" title="Issuance of shares, value">19,830 based on the stock price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20260410__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FGMKBusinessHoldingsLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFx3wu4XYhS5" title="Share price">1.28 on the date of the grant to a related party, FGMK Business Holdings, LLC, in payment for their accounting, tax and valuation services rendered. On April 10, 2026, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20260410__20260410__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAndDevelopmentServicesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcwVfdLbvw56" title="Number of restricted shares of common stock issued">105,824 restricted shares of Common Stock having a value of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20260410__20260410__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAndDevelopmentServicesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zmUq2KzWbJb4" title="Value of restricted shares of common stock issued">135,456 based on the stock price of $<span id="xdx_904_eus-gaap--SharePrice_iI_c20260410__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ResearchAndDevelopmentServicesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpDliNeayOZd" title="Share price">1.28 on the date of the grant to a service provider in consideration of research and development services rendered.

1488082

1.28

7951

14550

1.83

15492

19830

1.28

105824

135456

1.28

false false false false false false